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Abstract 
 
The oncofetal IGF2-mRNA binding protein 1 (IMP1) is overexpressed in cancer and 
is thought to promote cancer by binding and stabilizing oncogenic mRNAs. However, the 
regulation of IMP1 expression remains poorly understood. This study shows for the first time 
that IMP1 expression is regulated by apurinic/apyrimidinic endonuclease 1 (APE1) in HepG2 
liver cancer cells. The underlying mechanism whereby IMP1 is regulated by APE1 was 
investigated. APE1 was found to regulate IMP1 expression at the translational level without 
altering IMP1 mRNA expression. Evidence provided shows that the translational control of 
IMP1 by APE1 was at least partially attributed to the 3’UTR of IMP1. The combined studies 
from our laboratory suggest that APE1 is involved in the process of translation likely through 
regulating ribosome assembly and recruitment of IMP1 mRNA. Finally, this study shows that 
APE1’s role in regulating cell invasion is independent of IMP1. 
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Chapter 1 Introduction 
1.1 Overview 
IGF2 mRNA-binding protein 1 (IGF2BP1), also known as IMP1 in human and CRD-
BP in mouse, is an mRNA binding protein that is required during fetal development but is 
absent in adults (Leeds et al., 1997). However, IMP1 is overexpressed in various cancer 
types including liver, testicular, breast and lung cancer  (Ioannidis et al., 2003, 2004; 
Hammer et al., 2005; Bell et al., 2013; Gutschner et al., 2014). It is thought that IMP1 plays 
an important role in promoting and sustaining carcinogenesis and invasion through its ability 
to bind specific oncogenic mRNAs such as c-myc, CD44 and K-Ras (Prokipcak et al., 1994; 
Vikesaa et al., 2006; Mongroo et al., 2011). However, the regulation of IMP1 expression in 
cancer is not well studied. APE1 is a multifunctional protein involved in critical cellular 
pathways such as its role as the main endonuclease in the DNA base excision repair (BER) 
pathway and its role as redox coactivator of  important transcription factors including P53 
and AP-1 (Tell et al., 2009). APE1 also regulates post-transcriptional expression through its 
ability to cleave mRNAs such as c-myc (Barnes et al., 2009). Altered APE1 function, level 
and subcellular localization has been associated with a plethora of diseases including cancer 
(Hadi et al., 2000; Tell et al., 2005; Gu et al., 2009, 2011; Kim et al., 2014;). The aim of this 
thesis is to enhance the current understanding of IMP1 expression regulation and particularly 
by APE1 in cancer cells.  
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1.2 Apurinic/apyrimidinic endonuclease 1 (APE1)  
1.2.1 Structure and function 
The apurinic/apyrimidinic endonuclease 1 (APE1) is a multifunctional protein critical 
in the regulation of gene expression and the maintenance of genomic stability. APE1 is 318 
amino acids and approximately 37 kDa (Evans et al., 2000). The first 61 residues of APE1 
form an N-terminal extension. The rest of APE1’s residues form a globular protein made of 
two similar domains. Each domain consists of a six-stranded β sheet (2 or 3 of these strands 
are antiparallel) surrounded by α helices. The two domains of APE1 together form a four-
layered α/β sandwich (Gorman et al., 1997). 
APE1 is involved in multiple critical cellular pathways including: 1) acting as the 
main endonuclease in the DNA base excision repair (BER) pathway (Demple et al., 1991). 2) 
activating transcription factors via its redox activity (Xanthoudakis & Curran, 1992). 3) 
controlling mRNA expression through its endoribonuclease activity (Barnes et al., 2009). 4) 
regulating rRNA metabolism and interacting with proteins involved in ribosome biogenesis 
(Vascotto et al., 2009). 5) controlling the expression of miRNAs (Dai et al., 2013; Antoniali 
et al., 2017) 
A single base in DNA can be chemically damaged by multiple mechanisms including 
oxidation, alkylation and deamination. The first step in the DNA base excision repair (BER) 
pathway is the recognition and then the removal of the damaged base by a DNA glycosylase 
leaving behind an apurinic/apyrimidinic (AP) site. APE1 is the main endonuclease in the 
BER pathway which cleaves the DNA phosphodiester backbone 5’ to the AP site generating 
3’-OH and 5’-deoxyribose phosphate terminals. Other enzymes including DNA polymerase 
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and ligases are then recruited to complete the repairing of the DNA strand break (Demple et 
al., 1991; Quadrifoglio et al., 2009). APE1 also has other DNA nuclease activities that are 
involved in maintaining DNA integrity. These include APE1’s 3’-5’ DNA exonuclease 
activity as well as APE1’s 3’ DNA phosphatase activity (Tell et al., 2010).      
APE1 also regulates gene expression at the transcriptional level via its redox activity 
(Masuda et al., 1998). The redox status in the cell depends on the balance between the 
production of reactive oxygen species (e.g. during cellular respiration) and the activity of the 
antioxidant systems in the cell. Interestingly, the redox status in the cell affects gene 
expression by modulating the redox state of the reactive cysteine residues located within the 
DNA-binding domain of transcription factors (Tell et al., 2005). APE1 has been identified as 
a redox coactivator of many transcription factors including activator protein 1 (AP-1), the 
early growth response protein-1 (Egr-1), tumor suppressor P53 and nuclear factor-κB (NF-
κB) (Xanthoudakis & Curran, 1992; Huang & Adamson, 1993; Gaiddon et al., 1999; Nishi et 
al., 2002) . Using its nuclear redox activity, APE1 maintains the reactive cysteine residues 
within the DNA-binding domains of transcription factors in a reduced state which allows 
transcription factors to bind to their DNA target sites (Tell et al., 2009). In vitro assays have 
shown that the Cys65 residue of APE1 is responsible for the redox activity of APE1 
(Robbins et al., 1991; Masuda et al., 1998).       
APE1 also regulates gene expression at the post-transcriptional level through mRNA 
decay. APE1, which was purified from rat liver polysomes, was identified in Dr. Lee’s lab as 
an endoribonuclease that is capable of cleaving at the coding region of c-myc mRNA in vitro 
(Barnes et al., 2009). This was further confirmed as when APE1 was knocked down in HeLa 
cells the steady state levels of c-myc mRNA and its half-life increased (Barnes et al., 2009). 
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C-myc is a transcription factor that regulates genes involved in critical processes including 
cell cycle and apoptosis and its dysregulation can promote the genesis of tumors (Dang et al., 
1999). Later in vitro studies showed that APE1 can cleave other RNAs including CD44 
mRNA (Kim et al., 2010). APE1 cleaves single-stranded RNAs preferentially between UA, 
CA and UG dinucleotides and less preferentially between UC, CU, AC, and AU 
dinucleotides (Kim et al., 2010). This suggests that APE1 may be involved in cleaving a 
wide variety of RNA species. Indeed, APE1 was shown previously to cleave miRNA and 
viral RNA in vitro (Kim et al., 2010). It remains to be determined if the endoribonucleolytic 
activity of APE1 has other biological functions in cells.  
APE1 has also been implicated in rRNA cleansing and ribosome biogenesis. In a 
study aiming to identify APE1 protein partners, five out of ten proteins that were found to be 
part of APE1 complexes were either ribosomal proteins such as the 40S ribosomal protein 
SA (RPSA) and the 60S ribosomal protein P0 (RPLP0) or were involved in ribosome 
biogenesis and rRNA processing such as Nucleophosmin 1 (NPM1) (Vascotto et al., 2009). 
Nucleophosmin (NPM1), which is a nucleolar protein, was shown to physically interact with 
the 33 N-terminal residues of APE1. The interaction between APE1, NPM1 and RNA is 
required for the translocation of APE1 to the nucleolus and for regulating the cleansing of 
rRNA. In support of this, APE1 was shown to associate with 47S, 28S and 18S rRNA which 
are synthesized in the nucleolus (Vascotto et al., 2009). While knocking down APE1 in HeLa 
cells did not decrease rRNA synthesis, it did cause the accumulation of oxidized and 
damaged rRNA and also reduced protein synthesis (Vascotto et al., 2009). These findings 
confirmed the role of APE1 in cleansing oxidized damaged rRNA. Functional non-oxidized 
rRNAs are required for ribosomes to function in the translation process. APE1’s role in 
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translation was further emphasized when APE1 depleted cells showed a decrease in total 
amount of protein as compared to the control (Vascotto et al., 2009). Furthermore, RNA 
oxidation is thought to impair APE1-NPM1 interaction. The interaction of NPM1 with the N-
terminal of APE1 was shown to increase APE1’s AP-DNA endonuclease activity while 
reducing its abasic RNA endonuclease activity (Vascotto et al., 2009).  
Another identified role of APE1 is its involvement in regulating the expression of 
microRNAs (miRNAs). The discovery of miRNA molecules allowed the interpretation of 
many indirect protein interactions. The binding of miRNAs to the 3’UTR region of mRNAs 
represses the translation of these mRNAs. In vitro studies performed in our lab showed that 
APE1 can cleave microRNAs miR21 and miR10b (Kim et al., 2010). This was the first 
evidence for APE1 being involved in regulating miRNA expression. In another study, APE1 
knockdown in human HOS cells caused a statistically significant change in the expression of 
13 miRNAs (at least 2-fold change) (Dai et al., 2013). Seven of these were upregulated (hsa-
miR-451, hsa-miR-1290, hsa-miR-765, hsa-miR-483-5p, hsa-miR-513a-5p, hsa-miR-129-5p 
and hsa-miR-31). The other six were downregulated (hsa-miR-29b, hsa-miR- 197, hsa-let-7b, 
hsa-miR-324-5p, hsa-let-7i and hsa-miR-484) (Dai et al., 2013). The upregulation of some 
miRNAs while other miRNAs were downregulated upon APE1 knockdown suggests that 
APE1’s regulation of miRNAs is not necessarily restricted to its RNA cleaving ability but 
may involve its other functions such as its redox activity. Another recent study also showed 
that the knockdown of APE1 resulted in changes in miRNA expression in HeLa cells 
(Antoniali et al., 2017). The study also showed that APE1 regulates the tumor suppressor 
protein PTEN via processing miR-221/222. The same study showed that APE1 plays a role 
in pri-miRNA processing and stability by interacting with the DROSHA-processing complex 
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during cellular stress caused by genotoxicity (Antoniali et al., 2017). APE1’s regulation of 
miRNAs will help understand APE1’s role in diseases including cancer which is known to be 
at least partially driven by changes in expression of miRNAs (Boyerinas et al., 2008).       
APE1 has two functionally distinct domains. The C-terminus domain of APE1 is 
thought to be responsible for all the nuclease activities of APE1 (Masuda et al., 1998; Barnes 
et al., 2009; Kim et al., 2011). Amino acids His309, Glu96 and Asp210 of APE1 were 
particularly shown to play an essential role in these nuclease activities (Mol et al., 2000; 
Wilson & Barsky, 2001). The N-terminus domain is responsible for APE1’s redox activity 
(particularly residue Cys65) while also containing the nuclear localization sequence (Robbins 
et al., 1991; Masuda et al., 1998). Also, the first 33 N-terminal amino acids of APE1 was  
shown to be essential for stabilizing its interaction with other proteins (Vascotto et al., 2009).             
1.2.2 APE1 population variants  
The complete loss of APE1 is lethal in both in vitro and in vivo models (Illuzzi et al., 
2013). However, the partial loss of APE1 function due to genetic mutations is thought to be 
associated with diseases (Illuzzi et al., 2013). The most common APE1 variant is the D148E 
substitution which is observed at 46% frequency (Wilson et al., 2011). Increasing number of 
studies have linked the D148E variant with several cancer types including gastric, bladder 
and breast cancer (Smith et al., 2008; Gu et al., 2009; Lee et al., 2016; Lirussi et al., 2016) 
despite other studies reporting no association between this variant and cancer (Chang et al., 
2009; Y. Zhang et al., 2006). Also APE1 variant R237C was associated with endometrial 
cancer (Pieretti et al., 2001). Furthermore, out of all the APE1 variants, only D148E and 
Q51H variants were observed when the APE1 gene was re-sequenced in the 60 cancer cells 
lines of the NC-60 panel as well as HeLa and T98G cell lines (Illuzzi et al., 2013).     
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Several APE1 variants were linked to amyotrophic lateral sclerosis disease (ALS) 
(Olkowski, 1998). ALS is a serious motor neuron disease that causes gradual paralysis. In an 
ALS patient, the degeneration of nerves cells causes the brain to become unable to 
communicate with the muscles of the body which causes muscle weakness and atrophy 
(Zarei et al., 2015). Olkowski found that ALS patients were associated with APE1 variants 
L104R, E126D, D148E, D283G and G306A. The healthy individuals used as a control in the 
study did not have amino acid changes in APE1 (Olkowski, 1998). However, in another 
study involving a larger sample size, the D148E variant was found in both sporadic ALS 
patients and healthy individuals, and none of the ALS patients had other APE1 variants 
(Hayward et al., 1999).    
The possible association of APE1 variants with diseases suggested that these variants 
may have abolished or altered functions. In an in vitro study, the AP-DNA endonuclease 
activity of APE1 variants was assessed by measuring their ability to cleave an 18-bp DNA 
containing an AP site (Kim et al., 2014). The results showed that APE1 variants Q51H, 
I64V, D148E, E126D, G241R, and G306A had no change in AP-DNA endonuclease activity. 
L104R variant showed a 26% decrease in AP-DNA endonuclease activity. The R237A 
variant showed a complete loss of AP-DNA endonuclease activity (Kim et al., 2014).  
The RNA cleaving activity of APE1 variants was also assessed in the same study by 
measuring their ability to cleave an 88-nucleotide long c-myc RNA. APE1 variants Q51H, 
D148E, G241R, R237A and G306A showed significantly diminished RNA cleaving activity 
(76-85%). Furthermore, the L104R and E126D cleaved RNA at unique sequences different 
than the sequences cleaved by wild-type APE1 (Kim et al., 2014). Also, overexpressing 
APE1 L104R and E126D in E. coli Origami cells had stronger cytotoxicity, indicating that 
 8 
 
the these two variants with altered RNA cleaving activity as shown in vitro had stronger 
biological consequences in vivo (Kim et al., 2014). 
These functional characterization studies for the aforementioned APE1 variants 
showed that their AP-DNA endonuclease activity is for the most part unaffected except for 
R237A. The loss of AP-DNA endonuclease activity would impair the cell’s ability to repair 
damaged DNA. This would result in the accumulation of damaged DNA which is likely to 
eventually lead to cell death (Dang, 1999). This may explain why APE1 variants with loss of 
AP-DNA endonuclease activity were not commonly observed. Furthermore, the RNA 
cleaving activity of APE1 variants including D148E, E126D and L104R, which were 
possibly associated with diseases, was dramatically affected. Taken together, this suggests 
that the loss of APE1’s RNA cleaving ability may be implicated in the development of 
diseases such as ALS and cancer.      
As APE1 can cleave specific mRNAs such as c-myc which was previously identified 
as an mRNA that is stabilized and protected by IMP1 (Noubissi et al., 2006; Barnes et al., 
2009), this suggested that IMP1 may be physically shielding specific mRNAs from being 
cleaved by APE1. This possibility was the triggering factor for studying the possible 
connection between APE1 and IMP1 in cancer cells in this thesis. In an attempt to study the 
endoribonuclease function of APE1 in isolation, some of these APE1 variants, namely 
D148E, L104R and E126D which have lost or altered RNA cleaving activity, are being tested 
in vivo to find a possible link between the endoribonuclease activity of APE1 and IMP1.    
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1.2.3 APE1 subcellular localization 
 APE1 is mainly localized in the nucleus in normal tissue. However, the expression of 
APE1 in the cytoplasm was also reported in normal tissue including hepatocytes, superficial 
cells of gastrointestinal tract and epithelium of the prostate glands  (Duguid et al, 1995; 
Kakolyris et al., 1998; Tell et al., 2005). Increasing number of studies show that cytoplasmic 
localization of APE1 is associated with metabolic and proliferative disorders (Choi et al., 
2013). In fact, cytoplasmic expression of APE1 has been strongly associatied with increased 
tumor aggrivessness in liver, lung, epithelial ovarian, breast and other types of cancer (Moore 
et al., 2000; Puglisi et al., 2001, 2002; Di Maso et al., 2007).  
Based on its currently identified functions, APE1 can have a few possible roles in the 
cytoplasm. Studies have shown that APE1 plays a role in maintaing mitochondrial DNA 
(mtDNA) integrity in the cytoplasm (Ballista-Hernandez et al., 2017). Also, APE1 activates 
transcription factors which are involved in regulating the cell cyle, cell growth and apoptosis 
such as AP-1, NF-κB and P53 (Xanthoudakis & Curran, 1992; Gaiddon et al., 1999; Nishi et 
al., 2002). Furthermore, APE1 was also identified in Dr. Lee’s lab as an endoribonuclease 
that can regulate mRNA expression. APE1 was shown to cleave mRNAs such c-myc and 
CD44 in vitro and was also shown to regulate level and half-life of c-myc mRNA in HeLa 
cells (Barnes et al., 2009; Kim et al., 2010). C-myc is a transcription factor which binds to 
genes known to be involved in critical processes such as cell cycle, cell growth and apoptosis 
(Dang, 1999). Therefore, overexpression of c-myc causes increased cell proliferation and 
tumorigenesis. Insights into APE1’s role in the cytoplasm were also provided by 
experimental work in Dr. Lee’s lab. It was found that when the cytoplasmic extract of HepG2 
cells (post 16,000 x g centrifugation supernatant) was loaded on a sucrose gradient to 
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fractionate the 40S and 60S ribosomal subunits from the 80S ribosomes and polysomes, 
APE1 was found to co-sediment with the 40S and 60S ribosomal subunits. This suggests that 
APE1 may be involved in ribosome assembly. It was also shown that when APE1 was 
knocked down, the ribosomal protein RPS6, which is a component of the 40S subunit, shifts 
to the 80S ribosome (unpublished data). These results further support that APE1 regulates 
ribosome assembly/biogenesis. Thus, despite early studies on the DNA repair function of 
APE1 have mainly focused on the nucleus, later studies have provided evidence that 
cytoplasmic APE1 may be more important, especially when studying its ability to cleave 
mRNAs which are likely localized to the cytoplasm with close proximity to ribosomes or its 
related-structures. 
This thesis is aimed at finding a possible connection between the endoribonucleolytic 
function of APE1 and IMP1 which presumbly protects mRNA targets of APE1. Since 
cytoplasmic localization is required for the endoribonucleolytic function of APE1 mRNAs, it 
would be relevant to use a model system where cytoplasmic APE1 is abundant.  HepG2 cells, 
a liver cancer cell line which expresses high levels of cytoplasmic APE1 (unpublished) have 
thus been selected as a model system for this thesis.  Also, APE1’s endonucleolytic activity 
was first discovered in rat liver (Lee et al., 1998). Thus it would be relevant to choose a liver 
cell line as a model where the RNA cleaving activity of APE1 is expected to play an 
important role in the cytoplasm.  
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1.3 IGF2-mRNA binding protein 1 (IMP1) 
1.3.1 Structure and function 
The human IMP1, also known as CRD-BP in mouse, is an mRNA binding protein 
that is involved in mRNA stabilization, localization and translational control. IMP1 is 
abundant and necessary during fetal development but is normally absent in adults (Leeds et 
al., 1997). Remarkably, IMP1 was found to be overexpressed in many cancer types including 
liver, testicular, breast, brain and lung cancer (Ioannidis et al., 2003, 2004; Hammer et al., 
2005; Bell et al., 2013; Gutschner et al., 2014). The overexpression of IMP1 in a wide range 
of cancer types makes understanding its regulation of particular interest.  
IMP1 is a member of the VICKZ family of proteins which characteristically have two 
RNA recognition motifs (RRM) at the N-terminus and four K-homology (KH) domains at 
the C-terminus (Yisraeli, 2005). The RRM domain is around 90 amino acids long and has a 
β-α-β-β-α-β topology while the KH domain is around 70 amino acids long and has a β-α-α-β-
β-α topology (Yisraeli, 2005; Valverde et al., 2008). Studies have shown that it is the KH 
domains that allow IMP1 to bind single-stranded mRNAs (Chao et al., 2010). In each KH 
domain, the mRNA binding cleft consists of the highly conserved GXXG loop, α1-helix, α2-
helix, β2-strand, and a variable loop (Valverde et al., 2008). N-IMP1, an isoform of IMP1 
that is missing the two N-terminal RRM domains, is the most common isoform in normal and 
cancerous breast tissue. Many studies used antibodies against epitopes located in the RRM 
domains and thus the level of IMP1 has been underestimated in breast cancer cells 
(Fakhraldeen et al., 2015).   
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1.3.2 IMP1’s role in stabilizing oncogenic mRNAs 
Although the exact role of IMP1 in cancer is not completely understood, it is thought 
that IMP1 promotes cancer post-transcriptionally by stabilizing and protecting several 
oncogenic mRNAs from being cleaved by endoribonucleases (King et al., 2014). One of 
IMP1’s important mRNA targets is the oncogene c-myc. IMP1 binds to the coding region of 
c-myc mRNA and protects it from endoribonuclealytic attacks and thus increases the half-life 
of c-myc mRNA in the cell. This allows the overexpression of c-myc which leads to 
increased cell proliferation and tumorigenesis (Sparanese & Lee, 2007). IMP1 has also been 
found to bind to both the coding region and the 3’UTR of the proto-oncogene K-Ras which 
induces further increase in K-Ras and in c-myc expression in colon cancer (Mongroo et al., 
2011). 
IMP1 also binds to the mRNA coding region of β-transducin repeat-containing 
protein (βTrCP1). βTrCP1 promotes the degradation of several factors including the tumor 
suppressor protein BimEl. When IMP1 binds and stabilizes βTrCP1 mRNA, the tumor 
suppressor BimEl is downregulated which allows cells to escape apoptosis and cause 
tumorigenesis (Noubissi et al., 2006). IMP1 also binds and stabilizes CD44 mRNA thus 
causing CD44 to be overexpressed in cells (Vikesaa et al., 2006). The overexpression of 
CD44 induces the cells to structurally remodel their cytoskeleton to form invadopodia. 
Invadopodia are actin-rich cell membrane protrusions that give cells the ability to migrate 
and degrade the extracellular matrix (ECM) by recruiting membrane-type 1 matrix 
metalloproteinase (MT-MMP). This allows cells to enter the bloodstream and cause 
metastasis (Artym et al., 2006; Vikesaa et al., 2006).  
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Contrary to the aforementioned roles of IMP1 in promoting cancer, IMP1 also 
appears to have a tumor suppressive role in certain cancers. For instance, a study showed that 
knocking down IMP1 in leukemia cells caused cell proliferation (Liao et al., 2004). Another 
study showed that IMP1 suppresses cell invasion in metastatic breast cancer by stabilizing 
and localizing mRNAs encoding proteins involved in mediating cell-cell adhesion including 
E-cadherin, β-actin and α-actinin (Gu et al., 2012). The combination of mRNAs that IMP1 
binds to, which appears to be cell-specific, determines whether IMP1 acts as a tumor driver 
or suppressor.  
1.3.3 Regulation of IMP1 expression 
IMP1 transcription is at least partially activated by the Wnt-signalling pathway. 
Studies have shown that Wnt-signalling transcription factors β-catenin and TCF4 bind to the 
promoter of IMP1 and induces its transcription in HEK293 cells (Noubissi et al., 2006). In 
support of this, it was also shown that downregulation of the IMP1 can result from its 
promoter being methylated which modifies the chromatin structure and prevents β-catenin 
from binding and inducing transcription (Gu et al., 2009). IMP1 also binds and stabilizes β-
catenin mRNA which causes β-catenin to be overexpressed. Therefore, IMP1 and β-catenin 
form a positive-feedback loop (Gu et al., 2009). However, it was reported that the 
overexpression of IMP1 in HEK293 cells cannot be explained only by the β-catenin/TCF 
signalling pathway (Gu et al., 2008). Another factor implicated in IMP1’s transcriptional 
regulation is c-myc. As a transcription factor, c-myc binds to the promoter of IMP1 and 
enhances its transcription (Noubissi et al., 2011). As mentioned earlier, IMP1 also induces c-
myc expression by binding and stabilizing c-myc mRNA. Thus, it appears that IMP1 also 
forms a positive-feedback loop with c-myc (Noubissi et al., 2011).      
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The Let-7 group of miRNAs has been strongly implicated in regulating IMP1 
expression at the post-transcriptional level. Let-7 act as a tumor suppressor by binding and 
either inhibiting mRNA translation or inducing mRNA decay (Kuersten & Goodwin, 2003). 
In one study, the introduction of Let-7b in HepG2 cells was associated with a remarkable 
downregulation of IMP1, LIN28B which is also an RNA-binding protein, and the 
transcriptional factor HMGA2 (Boyerinas et al., 2008). Also introduction of Let-7d and Let-
7g into A549 cells, which normally express low endogenous levels of Let-7, caused the 
downregulation of IMP1. Consistently, inhibiting Let-7 in HeLa cells, which show high 
endogenous Let-7 expression, by transfecting Let-7 antisense oligonucleotides resulted in the 
elevation of IMP1 levels (Boyerinas et al., 2008).  
IMP1 has six Let-7 complementary sequences (LCS) in its 3’UTR (figure 1.1). The 
importance of the 3’UTR of IMP1 mRNA was evident when Let-7 or Let-7 inhibitor were 
transfected in cells which were already transfected with a luciferase fused to the 3’UTR of 
IMP1. Let-7 introduction repressed the luciferase activity and consistently the introduction of 
the Let-7 inhibitor allowed for higher luciferase activity (Boyerinas et al., 2008). The 
specificity of Let-7 was further confirmed when IMP1 3’UTR Let-7 complementary 
sequences LCS2 and LCS5 were mutated in the luciferase assay experiment. As expected, 
introduction of Let-7 into the cells no longer affected the luciferase activity (Boyerinas et al., 
2008). Furthermore, the shortening of IMP1 3’UTR has been observed in cancer cells. As a 
result, IMP1 levels are upregulated partially because Let-7 loses its ability to bind and 
repress IMP1 (Mayr & Bartel, 2009). 
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studies show that IMP1 3’UTR is targeted and regulated by multiple miRNAs and most 
dominantly by the Let-7 family which have a profound impact on IMP1 protein levels.   
Lin28B, an RNA-binding protein which is overexpressed in several cancers, is also 
negatively regulated by Let-7. On the flip side, Lin28B also negatively regulates Let-7 
biogenesis by preventing proper processing of pre-Let-7 which results in Let-7 degradation 
(Busch et al., 2016). By downregulating Let-7 in cancer cells, Lin28B not only enhances its 
own expression but also the expression of other oncogenes that are normally repressed by 
Let-7 including IMP1 and HMGA2. Furthermore, IMP1 enhances the expression of itself, 
Lin28B and HMGA2 by protecting their respective mRNAs from endoribonuclease attacks. 
IMP1 likely does so by binding to these mRNAs and forming mRNP complexes that are free 
of Let-7 miRNAs and AGO2 proteins which are required for RNA-mediated gene silencing 
(Busch et al., 2016). HMGA2, which is a transcription factor, upregulates IMP1 at the 
transcriptional level. As a result, these three proteins form a self-promoting triangle and are 
all negatively regulated by Let-7 (Busch et al., 2016). 
 In summary, IMP1 transcription is activated by the Wnt/β-catenin signalling pathway 
as well as by other transcription factors including c-myc and HMGA2. At the post-
transcriptional level, miRNAs and particularly Let-7 have a strong influence on IMP1 mRNA 
expression. Also, RNA-binding proteins have been shown to regulate IMP1 mRNA 
expression including IMP1 itself and indirectly by Lin28B which represses Let-7 maturation.  
1.3.4 Possible connection between IMP1 and APE1 
IMP1 as discussed earlier binds to several cancer-associated mRNAs and shields 
them from degradation by endoribonucleases. IMP1 has been shown to bind to the coding 
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region determinant (CRD) of c-myc mRNA and is thought to protect c-myc’s CRD from 
being cleaved by endoribonucleases (Sparanese & Lee, 2007). Interestingly, APE1 has been 
identified as an endoribonuclease that can cleave single-stranded RNAs, including c-myc. In 
fact, APE1 has been shown to cleave preferentially within the coding region determinant in 
c-myc and CD44 mRNA which are known to be physically shielded and protected by IMP1 
(Sparanese & Lee, 2007; Barnes et al., 2009). In support of this, the knockdown of APE1 in 
HeLa cells caused increased c-myc mRNA level and half-life (Barnes et al., 2009). These 
findings gave rise to the speculation that IMP1 possibly shields c-myc and perhaps other 
mRNAs from being cleaved by APE1. Thus, APE1 and IMP1 may be involved in a yin and 
yang relationship to regulate the expression of oncogenic mRNAs in cancer cells. However, 
no experimental work has been done yet to study IMP1 and APE1 as opposing partners in 
controlling mRNAs. Thus, the initial preliminary work of this thesis was to investigate this 
possible opposing effect of APE1 and IMP1 on oncogenic mRNAs. However, the initial 
experiments showed a lack of expression of CD44 and a low expression of c-myc. 
Surprisingly however, the initial experiments showed a strong regulation of IMP1 protein 
levels by APE1 expression. Hence, the aim of this thesis shifted towards enhancing the 
understanding of IMP1 expression and particularly by APE1 in cancer cells.  
1.4 Post-transcriptional regulation of gene expression 
1.4.1 mRNA stability 
After transcription, the level of mRNAs present in the cell depends on the balance 
between mRNA stability and degradation. The basic stabilization that each mRNA receives 
in the cell includes the addition of a 7-methylguanosine cap to the 5’-end and a poly-A tail to 
the 3’-end. The 7-methylguanosine cap is added to the 5’-end shortly after transcription has 
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been initiated and protects the mRNA from exoribonuclease attacks. The 5’-end cap is 
involved in other important roles including mRNA transport and serving as a binding site for 
translation initiation factors such as the eIF4E complex (Garneau et al., 2007; Karaki et al., 
2015). Once the mRNA has been released from the ribosome, the cell adds a poly-A tail to 
the 3’-end of mRNA. In eukaryotes, the poly-A tail is around 200-250 nucleotides long. The 
poly-A tail also plays a role in the transport of the mRNA to the cytoplasm (Wolf & 
Passmore, 2014). Also, poly-A binding protein (PABP) binds to the poly-A tail and protects 
mRNAs from random exoribonuclease attacks (Zhao, et al., 1999). These two stabilizing 
events occur to almost every eukaryotic mRNA. There are other mRNA stabilization 
measures taken by the cell in a gene-specific manner such as RNA-binding proteins which 
can recognize and bind to specific mRNAs and protect them from endoribonuclease attacks. 
This is discussed in details in section 1.4.3.2.     
1.4.2 mRNA degradation 
The cell has ways to degrade mRNA even after undergoing the stabilization events. 
mRNA degradation can be divided into three general pathways: deadenylation-dependent 
decay, deadenylation-independent decay and endoribonucleolytic decay. In deadenylation-
dependent decay, the deadenylation is the rate-limiting step (Decker & Parker, 1993). 
Deadenylation is initiated by Pan2 and Pan3 proteins which bind to the 3’-end of the mRNA 
and shorten the poly-A tail by removing adenosine monophosphates (Brown & Sachs, 1998). 
After that, a protein complex named Ccr4-Not is recruited and removes the remainder of the 
poly-A tail (Tucker et al., 2001). There are also other nucleases involved in the 
deadenylation step. An important eukaryotic deadenylase is the poly(A)-specific ribonuclease 
(PARN) which is a metal-ion dependent exoribonuclease that specifically degrades the poly-
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A tail at the 3’-end of the mRNA (Virtanen et al., 2013). Following the deadenylation step, 
the mRNA can undergo either 5’ to 3’ decay or 3’ to 5’ decay (Wu & Brewer, 2012).  
In 5’ to 3’ decay, LSm1-7 protein complex binds to the 3’-end of the mRNA which 
triggers decapping enzymes 1 and 2 (DCP1 and DCP2) to remove the 5’-end 7-
methylguanosine cap (Steiger et al., 2003; Tharun et al., 2000). This then allows the 5'-3' 
exoribonuclease 1 (XRN1) to cleave the mRNA at the decapped 5’-end (He et al., 2003). In 
the 3’ to 5’ decay, initial 5’-end decapping is unnecessary. The mRNA is directly degraded 
from 3’ to 5’ by exosomes. Then, the 5’-cap is hydrolyzed by scavenger-decapping enzyme 
(DcpS) (Garneau et al., 2007). 
In deadenylation-independent decay, the interaction between ribosomal protein 28B 
(Rps28B) and enhancer of mRNA-decapping protein 3 (Edc3) on the poly-A tail of the 
mRNA recruits DCP1 and DCP2 to remove the 7-methylguanosine cap at the 5’end. After 
the 7-methylguanosine cap is removed, Xrn1 is recruited to degrade the rest of the mRNA 
(Garneau et al., 2007; He et al., 2014). 
In endoribonucleolytic decay, an endoribonuclease cleaves at internal sites in the 
mRNA generating two fragments that are accessible for degradation by exoribonucleases 
such as Xrn1 (Garneau et al., 2007). There are a few endoribonucleases that have been 
identified so far including APE1 which cleaves c-myc and other mRNAs and Zc3h12a which 
cleaves cytokine encoding mRNAs (Barnes et al., 2009; Matsushita et al., 2009). mRNA 
degradation generally occurs to achieve one of two goals. One is to degrade mRNAs that 
could be potentially translated into truncated peptides that are harmful to the cell. The other 
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is to control the level of expression of a specific gene in the cell depending on the cell’s 
needs (Schoenberg & Maquat, 2012).   
 There are also endoribonucleases, such as Ire1 and angiogenin, which cleave RNA to 
serve more specific functions (Sidrauski & Walter, 1997; Yamasaki et al., 2009). Ire1 is a 
transmembrane protein that is located in the endoplasmic reticulum (ER) or the inner nuclear 
membrane and has two enzymatic domains, a kinase and an endoribonuclease domain. Ire1 is 
part of the unfolded protein response (UPR) pathway that senses the accumulation of 
unfolded proteins in the lumen of the endoplasmic reticulum which leads to the activation of 
the endoribonuclease activity of Ire1 (Morl et al., 1993; Sidrauski & Walter, 1997). It is 
thought that the kinase activity of Ire1 is required to activate its endoribonuclease activity 
(Poothong et al., 2010). The active endoribonuclease domain of Ire1 splices specifically at 
two sites in the pre-mRNA of HAC1 to form mature mRNA that is then translated into 
functional HAC1 protein (Sidrauski & Walter, 1997). HAC1 as a transcription factor then 
activates the transcription of other UPR genes that enhances protein folding and assembly in 
the ER (Morl et al., 1993; Sidrauski & Walter, 1997). Also, angiogenin is a multifunctional 
protein which secretion is stimulated in response to hypoxic stress. Angiogenin binds to 
surface receptors of adjacent cells and then is internalized into cells to promote formation of 
new blood vessels (Yamasaki et al., 2009). One of angiogenin’s latest identified functions is 
its cleaving of tRNA in response to cellular stress. This tRNA cleaving ability of angiogenin 
serves to reduce translation of global proteins to conserve energy for repairing the damage 
inflicted in the cell due to hypoxic stress (Yamasaki et al., 2009). APE1 has been shown to 
regulate c-myc mRNA stability in Hela cells (Barnes et al., 2009) and cleave various RNA 
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species in vitro, including miRNA and viral RNA (Kim et al., 2010). Its exact biological 
function(s) to cleave RNAs in cells remain to be further explored. 
1.4.3 mRNA decay to regulate gene expression  
1.4.3.1 mRNAs containing cis-acting elements  
 
Cis-acting mRNA elements are sequences in the mRNA that serve as binding sites for 
RNA-binding proteins (RBPs). The effect that this has on the mRNA expression depends on 
the type of RBP involved (Wu & Brewer, 2012). One of the most common determinants of 
mRNA stability are the AU-rich elements (AREs) which are found in the 3’-untranslated 
region (3’UTR) of many mRNAs including those encoding inflammatory factors and proto-
oncogenes such as interleukin IL-3 and c-FOS, respectively (Stoecklin et al., 1994; Lautz et 
al., 2010). The effect AREs have on mRNA stability depends on ARE-binding proteins 
(ARE-BPs). Destabilizing ARE-BPs such as TTP, BRF1 and BRF2 bind to AREs in mRNAs 
and trigger the removal of the 3’-poly-A tails leading to the destabilization and degradation 
of mRNAs. This is then followed by 5′-to-3′ and 3′-to-5′ exonucleolytic degradation 
(Stoecklin et al., 1994; Lautz et al., 2010). GU-rich elements (GREs) are another example of 
cis-acting mRNA elements that can regulate mRNA stability by binding to proteins from the 
CELF family. CUGBP1 is an example of a CELF protein that binds to GU-rich mRNA 
elements and induces mRNA degradation (Vlasova et al., 2008). As described in the next 
section, RNA binding proteins (RBPs) are key players in gene expression regulation.  
1.4.3.2 RNA binding proteins and diseases 
 
RNA binding proteins (RBPs) are significant players in the post-transcriptional 
regulation of gene expression. RBPs bind to mature mRNAs and form ribonucleoprotein 
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(RNP) complexes. This allows RBPs to remain stably bound to mRNAs in RNP complexes 
and control what mRNAs are exposed to (Lukong et al., 2008). Therefore, RBPs can regulate 
all aspects of mRNA fate which includes their stability, subcellular location and translation 
(Gerstberger et al., 2014). The proper regulation of RBPs ensures that their mRNA targets 
are also located and expressed in accordance with the cellular needs. In fact, dysregulation of 
RBPs has been associated with diseases and most importantly cancer. As mentioned 
previously, IMP1 can bind and stabilize specific oncogenic mRNAs including c-myc, CD44 
and K-Ras (Prokipcak et al., 1994; Vikesaa et al., 2006; Mongroo et al., 2011) and is found 
to be overexpressed in many cancer types such as liver, testicular, breast and lung cancer 
(Ioannidis et al., 2003, 2004; Hammer et al., 2005; Bell et al., 2013; Gutschner et al., 2014). 
There are also RBPs that bind and regulate a broad range of mRNA targets. For 
example, the mammalian SAM68 protein, which belongs to the STAR family of RNA 
binding proteins, can bind to AU-rich elements which are commonly present in mRNAs. 
Therefore, SAM68 is involved in multiple cellular processes such as translational regulation, 
mRNA splicing and cellular signalling (Elliott & Rajan, 2010). The overexpression of 
SAM68 has been found to be associated with several cancers including breast and renal 
cancer (Zhang et al., 2009; Song et al., 2010). RBPs can also regulate the subcellular location 
of mRNAs in the cell. For example, FMRP is an RNA-binding protein which can regulate 
mRNA localization in neurons. The loss of FMRP in neurons affects the synaptic plasticity 
of neurons and is thought to be a major cause of the fragile x syndrome (FXS) disease which 
causes a range of developmental and learning problems (Bassel & Warren, 2008). As 
discussed in section 1.3.2, IMP1 is another RNA-binding protein which has multiple mRNA 
targets and controls the translation/stability of these mRNAs. Since many of these mRNAs 
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are highly implicated in cancer, it is of particular interest to study the regulation of IMP1 
expression.  
1.5 Translational regulation 
 Translation is the second major step after transcription in gene expression. 
Translational control often explains the poor correlation often observed between levels of 
mRNA transcripts and synthesized proteins. In the process of translation, the mRNA is read 
as a code to translate the DNA sequence to the amino acid sequence of a protein. A codon 
which consists of three bases on the mRNA encodes one specific amino acid. Mature 
mRNAs in eukaryotes are transported from the nucleus to the cytoplasm where the 
translational machineries known as ribosomes are located. Each ribosome consist of the large 
(60S) subunit and the small (40S) subunits which are initially separate in the cytoplasm but 
come together in the process of translation. These subunits are associated with proteins and 
RNA molecules including ribosomal RNA (rRNA) and transfer RNA (tRNA). During 
translation, one end of the tRNA reads the mRNA codon while the other end binds the 
corresponding amino acid (Chapeville et al., 1962).  
 In Eukaryotes, at least eleven initiation factor proteins are required for translation 
initiation. First, initiation factor eIF2 delivers a methionine-carrying tRNA to the P-site of the 
40S ribosomal unit forming a 43S pre-initiation complex. This pre-initiation complex is then 
delivered to the 5’-end of the mRNA by initiation factors eIF3 and eIF4. Together this 
complex scans the 5’UTR until it reaches the AUG start codon. The 60S ribosomal unit then 
joins this complex forming an 80S ribosome. This causes the initiator factors to be released 
and marks the start of the translation process. The methionine is the first amino acid to be 
incorporated into the growing polypeptide chain. However, for many proteins methionine is 
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later enzymatically removed (Poulin & Sonenberg, 2013). In a sucrose gradient fractionation 
experiment in Dr. Lee’s lab, APE1 was found to co-sediment with the 40S and 60S 
ribosomal subunits indicating that APE1 plays a role in ribosome assembly (unpublished 
data).   
The next step in translation is elongation. Another aminoacyl-tRNA binds with 
elongation factor eEF1A and a GTP forming a complex that binds to the mRNA codon at the 
empty A-site. This triggers GTP to be cleaved to GDP and is then released along with eEF1A 
to the cytoplasm. After that, the amino acid in the P-site forms a peptide bond with the amino 
acid in the A-site resulting in the P-site tRNA losing its amino acid. With the help of eEF2 
and GTP, the ribosome moves along the mRNA in 5’ to 3’ direction, a process called 
translocation. This causes the polypeptide-tRNA in the A-site to move to the P-site leaving 
the A-site ready to bind to the next aminoacyl-tRNA. Also, the tRNA that was in the P-site 
moves to the E-site which is then released to the cytoplasm. The released tRNAs, GDPs and 
elongation factors are recycled and used again in translation. The elongation process is 
repeated until the entire translatable region of the mRNA is read and the correct amino acids 
are added to the growing polypeptide chain in the correct order. Once this has been achieved 
and a stop codon is reached, translation is terminated and the polypeptide is released to the 
cytoplasm (Clancy & Brown, 2008). There are three codons that are not recognized by any 
tRNA and thus serve as termination signals. These are: UGA, UAA and UAG. Instead of 
tRNAs, two release factors eRF1 and eRF3 collaborate to recognize and bind these stop 
codons and catalyze the release of the polypeptide from the tRNA (Dever & Green, 2012). 
There are proteins which regulate translation by cleaving tRNAs. For example, angiogenin, 
which secretion is enhanced by hypoxic stress, cleaves tRNAs to repress translation in order 
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to conserve energy to repair the stress-induced damage (Yamasaki et al., 2009). APE1 is also 
capable of cleaving various RNA species in vitro, including miRNA and viral RNA (Kim et 
al., 2010). However, the exact biological role of the RNA cleaving function of APE1 is not 
understood yet. 
 Translational control of mature mRNAs allows for rapid regulation of protein levels 
in the cells. The majority of the translational control occurs at the translation initiation step. 
The activation of translation can be decreased during cellular stress or starvation by 
deactivating translation initiation factors (eIFs) (Sonenberg & Hinnebusch, 2009). However, 
translational control is further complicated when the role of the untranslated regions in 
mRNA are considered. These are called the 5’UTR and the 3’UTR (untranslated regions). 
Both regions have a significant impact on mRNA stability and translation efficiency by 
binding different factors such as microRNAs and regulatory proteins. The early finding that 
APE1 was purified from the ribosomal salt wash (Lee et al., 1998) and that APE1 co-
sediments with the ribosomal subunits in a sucrose gradient (unpublished) suggest that APE1 
may have a function role in translation regulation. 
1.5.1 The importance of the 5’UTR and 3’UTR in regulating mRNA translation  
 Proper mRNA translation requires factors binding at both its 5’UTR and 3’UTR. The 
translation pre-initiation complex which consists of the small ribosomal unit, methionyl-
tRNA, initiation factors (including eIF4E and eIF4G) and GTP is recruited to the 5’UTR by 
eIF4F. This allows the complex to scan down the 5’UTR until it reaches the AUG translation 
start codon which causes the GTP to be hydrolyzed, initiation factors to be released and the 
large ribosomal unit to bind to the pre-initiation complex. This creates a complete ribosome 
unit that can drive translation elongation (Kuersten & Goodwin, 2003). It has been found that 
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the physical interaction between the mRNA 5’UTR and 3’UTR is important during 
translation initiation. After the pre-initiation complex binds to the 5’UTR of the mRNA, the 
poly-A binding protein (PAB) at the 3’UTR interacts with eIF4E and eIF4G at the 5’UTR. 
This causes the joining of the 3’UTR with the 5’UTR and thus the circularization of the 
mRNA (Wells et al., 1998). This interaction between the two UTR regions stimulates 
translation (Kuersten & Goodwin, 2003). It is also thought that this circularized mRNA form 
enhances translational efficiency by facilitating the use of terminating ribosomes in a new 
round of translation (Wells et al., 1998).   
RNA binding proteins (RBPs) can regulate translational efficiency by binding to 
specific sequences that may exist anywhere on the mRNA but mostly in the 5’UTR and 
3’UTR regions. Some RBPs have been shown to repress translation by interfering with the 
interaction of eIF4G with eIF4E and poly-A binding protein (PAB) and the circularization of 
the mRNA structure during ribosome recruitment. For example, the Drosophila protein 
Bicoid binds to the 3’UTR of caudal mRNA and recruits eIF4E2 instead of eIF4E at the 5’-
cap structure. The much lower affinity of eIF4E2 (compared to eIF4E) to eIF4G interferes 
with the circularization of the mRNA and thus represses translation (Cho et al., 2005). The 
mammalian eIF4E2 has also been shown to cause translation repression (Morita et al., 2012).  
Other RBPs have been identified that also block the interaction between eIF4G and eIF4E on 
the mRNA to which they bind (Nakamura et al., 2004; Stebbins-boaz et al., 1999).   
There are other RBPs that can inhibit mRNA translation without interfering with the 
circularized mRNA structure. For example, as a consequence of inflammation, the GAIT 
complex binds to a region in the 3’UTR of ceruloplasmin mRNA. Then, a component of the 
GAIT complex known as L13a inhibits the interaction between eIF4G and eIF3 which halts 
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the recruitment of ribosomes for translation (Kapasi et al., 2008). In contrast to the other 
translation inhibition methods, the GAIT complex needs the mRNA to be in the circularized 
form in order to be placed in close proximity to its target and inhibit translation (Wells et al., 
1998).  
 Inhibition of translation can also take place at the elongation stage. For example, PUF 
and Argonaute (Ago) proteins form a complex that bind to the 3’UTR and disrupt eEF1A’s 
GTPase activity. This activity of eEF1A is needed during elongation to release empty tRNAs 
from the ribosome and thus inhibition of the GTPase activity of eEF1A prevents translation 
elongation (Friend et al., 2012).  
Translational control can also be mRNA selective. For instance, the heterogeneous 
nuclear ribonucleoprotein E1 (hnRNP E1) binds to a 33-nucleotide element in the 3’UTR of 
the mRNAs of Disabled-2 (Dap2) and interleukin-like EMT inducer (ILEI), which are both 
involved in promoting cell invasiveness, and represses their translation. The mechanism of 
their translational inhibition occurs at the elongation stage and requires the elongation factor 
eEF1A1. HnRNP1 E1 binds to eEF1A1 at the A-site and prevents its release from the 
ribosome. This inhibits the progression of the 80S ribosome and thus halts translation 
elongation. TFGβ stimulation activates a kinase cascade leading to the phosphorylation of 
hnRNP E1 by Akt-2 which causes the dissociation of hnRNP E1 from the 3’UTR mRNA and 
eEF1A1 which allows translation elongation to proceed (Hussey et al., 2012).  
Another example of mRNA specific translational regulation is the selective binding 
of the myogenic regulatory factor MYF5 to the 3’UTR as well as the coding region of Ccnd1 
mRNA promoting its translation. Interestingly MYF5 was also found to enhance Ccnd1 
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transcription (Panda et al., 2016). Furthermore, other RBPs can have different effects on 
different mRNAs. For example, NF90 binds to mRNAs containing AU-rich 3’UTRs such as 
VEGF and enhances their expression (Vumbaca et al., 2008). However, NF90 also binds to 
other mRNAs such as β-glucosidase and represses their translation (Xu & Grabowski, 2018). 
The 3’UTR region of the mRNA is a target site for microRNAs (miRNAs). miRNAs 
play a significant role in regulating mRNA stability and translation. The length of miRNAs is 
usually 20-24 nucleotides. Upon binding to the mRNA, if the miRNA is perfectly 
complementary to a sequence in the 3’UTR, the mRNA is usually degraded. However, if the 
miRNA does not form perfect base-pairing with a sequence in the 3’UTR, the translation of 
the mRNA is repressed without being degraded (Kuersten & Goodwin, 2003).  
RBPs can interfere with the effect of miRNAs or other RBPs on mRNAs. For 
example, Dnd1 binds to mRNA 3’UTR sites which are also targeted by miRNAs and thus 
prevents miRNAs from silencing mRNA expression (Kedde et al., 2007). In general, an 
mRNA transcript is a target for more than one RBP and other factors such as miRNAs. The 
fate of the mRNA will depend on the combinational effect of those RBPs and other factors. 
Altered APE1 expression has been shown to influence the level of miRNAs (Dai et al., 2013; 
Antoniali et al., 2017). Thus, it may be possible that APE1 is involved in translation 
regulation via controlling miRNA expression.   
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1.6 Hypothesis and Research Objectives 
IMP1 is absent in adults but overexpressed in various cancer types, including liver, 
testicular, brain, breast and lung cancer (Ioannidis et al., 2003, 2004; Hammer et al., 2005; 
Bell et al., 2013; Gutschner et al., 2014). In one study, it was shown that 116 RNA-binding 
proteins were overexpressed more than 2-fold in liver cancer cells (Gutschner et al., 2014). 
The most upregulated RBP in liver cancer cells was IMP1 (Gutschner et al., 2014). The same 
study showed that IMP1 depletion inhibited proliferation and induced apoptosis in several 
liver cancer cell lines and the strongest effect was observed in HepG2 cells (the cell line used 
in this thesis) (Gutschner et al., 2014). Furthermore, a study showed that IMP1 
overexpression enhances invasion and migratory properties in tumor-derived cells (Zirkel et 
al., 2013). Consistently, Zirkel et al. also showed that IMP1 knockdown causes the reversal 
of these invasion properties in tumor-derived cells and the enhancement of normal epithelial 
cell phenotype such as improved cell-to-cell adhesion and reduced migratory abilities (Zirkel 
et al., 2013). Taken all together, this implies that IMP1 is a particularly important promoter 
and sustainer of tumorigenesis and invasion in various cancer types. Despite the growing 
evidence of the importance of IMP1 in cancer, a comprehensive understanding of its 
regulation has not been reached yet. 
Our initial experiments showed that APE1 knockdown in HepG2 cells causes 
upregulation of IMP1 protein levels. Also, previous work in our lab showed that knocking 
down APE1 in HepG2 cancer cells gave the cells migratory and invasive abilities 
(unpublished data). This suggested that the invasion induced by APE1 knockdown may 
involve its regulation of IMP1 protein levels. There is currently no published work showing 
any interaction between these two proteins. Therefore, the aim of this thesis was to enhance 
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the understanding of IMP1 expression regulation in cancer cells and particularly by APE1. It 
was hypothesized that APE1 regulates IMP1 expression at the post-transcriptional level and 
that this regulation may explain the invasion induced by APE1 knockdown in HepG2 cells.  
The research objectives of this thesis are the following: 
1) To establish APE1’s regulation of IMP1 expression and determine whether this takes 
place at the transcriptional level or post-transcriptional level. To do this, APE1 was 
knocked down in HepG2 cells and then IMP1 mRNA and protein levels were determined 
using qRT-PCR and Western bot analysis, respectively.  
2) To determine if lost/altered RNA cleaving activity of APE1 affect its ability to 
regulate IMP1 levels. To do this, wild-type APE1 as well as APE1 variants D148E, E126D 
and L104R were stably transfected into cells. Then IMP1 protein levels were measured using 
Western blot analysis. D148E, E126D and L104R retain full or modest DNA endonuclease 
activity and maintain normal binding to RNA substrate but either lost RNA cleaving activity 
in the case of D148E or show an altered pattern of RNA cleaving activity in the case of 
E126D and L104R (Kim et al., 2014). Therefore, if the RNA cleaving ability of APE1 is 
required in its regulation of IMP1 levels, then it is expected that overexpressing one of these 
APE1 variants would have a lesser impact on IMP1 levels than overexpressing wild-type 
APE1. 
3) To determine if the translation of IMP1 regulated by APE1 is mediated by the 
3’UTR of IMP1. To do this, the 3’UTR of IMP1 was fused to a luciferase reporter construct. 
It was then tested if APE1 knockdown affects the expression of this luciferase reporter fused 
with different regions of the IMP1 3’UTR. 
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4) To determine if higher IMP1 expression as a result of APE1 depletion is due to 
defective protein degradation. This was tested by knocking down APE1 in cells and then 
performing the cycloheximide chase experiment. After cycloheximide treatment, proteins are 
expected to gradually degrade with time. Cell lysates were collected at different time-points 
and Western blot analysis was performed to measure IMP1 protein levels at each time-point 
in both APE1 knocked-down cells and SN-transfected cells (SN: scrambled negative 
control).  
5) To determine if enhanced invasion induced by APE1 knockdown (previously shown 
by matrigel invasion assay) is mediated by upregulation of IMP1. The initial plan was to 
knockdown IMP1 in APE1 knocked-down cells and then test if invasion induced by APE1 
knockdown is reversed by the knockdown of IMP1 using matrigel invasion assay. However, 
it was not possible to knockdown IMP1 in APE1 knocked-down cells for reasons discussed 
later in this thesis. Alternatively, the effect of the separate knockdown of APE1 and IMP1on 
E-Cadherin levels was determined using Western blot analysis. E-Cadherin is a pivotal cell 
adhesion protein and its loss is a strong indication of invasion phenotype (Gheldof & Berx, 
2013). If the invasion induced by APE1 knockdown is via its upregulation of IMP1, then 
APE1 knockdown is expected to affect E-Cadherin level in the reverse direction compared to 
the E-Cadherin level in IMP1 knocked-down cells. 
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Chapter 2 Materials and Methods  
2.1 Cell preparation  
The human hepatocellular carcinoma cell line HepG2 was used throughout this thesis. 
The HepG2 cells were purchased from the American Type Culture Collection (ATCC) 
organization and stored in liquid nitrogen medium containing 5% DMSO. When needed to be 
used, the cells were thawed in a 37°C water bath for 2 minutes and then transferred to a T-25 
flask. Enough volume of pre-warmed growth medium EMEM (BioWhittaker) containing 
10% fetal bovine serum (FBS) was added to the T-25 flask to make the final volume equal to 
10 mL. The cells were maintained at 37°C in a CO2 incubator. When the cells in the T-25 
flask reached ~80% confluency, they were split into two T-75 flasks. This was done by 
discarding the growth medium from the T-25 flask and then rinsing the cells with 2 mL PBS. 
Then, 1 mL of 0.25% trypsin-EDTA was added to the T-25 flask. The flask was incubated at 
37°C in a CO2 incubator for 10-13 minutes. When the cells detached from the flask’s surface, 
9 mL of pre-warmed EMEM+10%FBS was added to the flask to inactivate the 0.25% 
trypsin-EDTA. The cells were mixed thoroughly with the growth medium and then split into 
two T-75 flask. Then, enough EMEM+10%FBS was added to each T-75 flask such that the 
total volume in each flask is equal to 20 mL. The cells were maintained and passaged in T-75 
flasks at 37°C in a CO2 incubator. Cells were discarded after 10 passages.       
2.2 Knocking down gene expression using siRNA 
 This section describes the method used when knocking down one gene only in cells 
(i.e. either APE1 or IMP1). To knockdown the expression of a particular gene, HepG2 cells 
were transfected with siRNA against the gene of interest. HepG2 cells are known to be 
difficult to transfect and were transfected using the reverse transfection procedure as 
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described below. The sequences of the siRNAs used are listed in table 2.1. As a negative 
control, other cells were transfected with scrambled negative control siRNA (SN).  
Table  2.1 Sequences of siRNAs used to knockdown genes in cells. The sequences are 
comprised of ribonucleotides except nucleotides suffixed with (d) denoting 
deoxyribonucleotides.  
siRNA Duplex sequences 
siAPE1 
5’-GUCUGGUACGACUGGAGUACCGG(CA)d-3’ 
3’-UCCAGACCAUGCUGACCUCAUGGCCGU-5’ 
siCRD-BP-1 
5’-CCUGGCUGCUGUAGGUCUUUUCC-3’ 
3’-GGACCGACGACAUCCAGA AAAGG-5’ 
siCRD-BP-2 
5’-GGAGGA GAACUUCUUUGGUCCCAAG-3’ 
3’-UUCCUCCUCUUGAAGAAACCAGGGUUC-5’ 
SN 
5’-CUUCCUCUCUUUCUCUCCCUUGU(GA)d-3’ 
3’-AGGAAGGAGAGAAAGAGAGGGAACACU-5’ 
 
   To transfect siRNA into cells, siRNA- Lipofectamine 2000 complexes were prepared 
as follows (per well in a 6-well plate). Two μL of Lipofectamine 2000 was mixed with 248 
μL Opti-MEM in a tube. In a separate tube, 2.5 μL of 20 μM siRNA was mixed with 247.5 
μL Opti-MEM. Both mixtures were incubated at room temperature (RT) for 5 minutes. After 
5 minutes, the tubes were mixed and incubated for another 20 minutes at RT. During this 
period, the cells that would be transfected were prepared as follows. 
Cells in T-75 flask with 70-80% confluency were used. First, the growth medium was 
discarded and the cells were rinsed with 3 mL PBS. Then, 2 mL of 0.25% trypsin-EDTA was 
added to the flask. The flask was incubated at 37°C in a CO2 incubator for 10-13 minutes 
until the cells detached from the flask’s surface. Next, 18 mL of pre-warmed 
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EMEM+10%FBS was added to the flask to inactivate the 0.25% trypsin-EDTA. Cells were 
mixed thoroughly with the growth medium to ensure that the cells were evenly distributed.  
To determine the cell density in the T-75 flask, 50 μL of cells were thoroughly mixed 
with 50 μL trypan blue in an Eppendorf tube. Then, a portion of this trypan-cells mixture was 
applied to a glass hemocytometer. Using the 10X objective lens of a light microscope, the 
viable cells (which remain unstained since only non-viable cells take up trypan blue) were 
counted in all eight hemocytometer quadrants and then averaged. To calculate the number of 
viable cells per mL in the T-75 flask, the following equation was used: average number of 
viable cells x 2 x 104. Based on the calculated value, enough volume EMEM+10% FBS was 
added to the T-75 flask to obtain a cell density of 40 x 104  cells/mL. For every 2 mL of the 
newly diluted cell suspension (40 x 104  cells/mL), 0.5 mL transfection mixture was added. 
The cell suspension and the transfection mixture were first mixed in one tube (the total 
volume prepared depended on the number of wells required). Then 2.5 mL of this was 
pipetted into each well of a 6-well plate and then incubated at 37°C in a CO2 incubator.  
After 48 hours, the transfection procedure was repeated to enhance transfection 
efficiency. The only difference was that cells were taken this time from a 6-well plate instead 
of a T-75 flask. For each well, cells were washed with 0.5 mL PBS and then trypsinized 
using 300 μL 0.25% trypsin-EDTA. After incubating 10-13 minutes at 37°C in a CO2 
incubator, 2.5 mL of growth medium was added to stop trypsin. The rest of the transfection 
procedure was the same as explained before in this section. The cells were then incubated at 
37°C in a CO2 incubator.  
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2.3 Generating HepG2 cells stably transfected with APE1 variants 
Prior to joining Dr. Lee’s lab, Dr. Chow Lee and Dr. Maggie Li generated stable 
HepG2 cells expressing one of the following exogenous APE1 variants: wild-type APE1, 
L104R, E126D and D148E. Also generated were HepG2 cells transfected with an empty 
vector. The expression of the exogenous APE1 variants was confirmed by DNA sequencing.  
2.4 Total RNA extraction 
 After 24 hours from the last siRNA transfections as explained in section 2.2, the 
growth medium was discarded and cells were washed twice with 2 mL PBS. The mirVana 
miRNA isolation kit (Invitrogen, cat # AM1560) was used for RNA extraction which 
included the following: lysis buffer, homogenate additive, collection tubes, filter columns, 
wash solution 1 and wash solution 2/3. First, 200 µL lysis buffer was added to each well. The 
lysate from two wells were combined into a 1.5 mL Eppendorf tube. Then, 40 µL of 
homogenate additive was mixed with the lysate and incubated on ice for 10 minutes. Next, 
400 µL of phenol-chloroform was mixed with the lysate. The mixture was vortexed for 30-60 
seconds and then centrifuged at 10,000 x g for 5 minutes at RT. Two layers can be seen after 
the centrifugation and only the upper layer (while leaving the lower layer intact) was 
collected into a new tube and mixed with 1.25X 100% ethanol. The mixture was loaded into 
a filter column which was placed inside a collection tube and centrifuged at 10,000 x g for 15 
seconds. The flow-through was discarded and 700 µL of wash solution 1 was added to the 
filter column. The mixture was centrifuged at 10,000 x g for 15 seconds. Again, the flow-
through was discarded. Then, the filter column was washed twice with 500 µL wash solution 
2/3. After discarding the wash solution, the column was centrifuged once more at 10,000 x g 
for one minute to ensure all the wash solution has been removed. The filter was placed in a 
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new collection tube and 100µL nuclease-free water, which was heated to 95°C, was added to 
the filter column and then centrifuged at maximum speed for 30 seconds to elute the RNA 
into the collection tube. The RNA samples were quantified using NanoDrop 1000 
spectrophotometer (Thermo Scientific, Illinois, USA). The RNA quality was checked by 
comparing the A260/A280 ratio for the RNA samples against the 1.8-2.0 ratios for pure RNA. 
2.4.1 DNase treatment, cDNA synthesis and qRT-PCR 
 In order to remove contaminating DNA, the collected RNA samples were processed 
with the DNase treatment & removal kit (Invitrogen, cat # 1906). First, 0.1 volume 10X 
DNase I buffer and 1 µL rDNase I were added to 1 µg RNA and mixed gently. The mixture 
was incubated at 37°C for 20-30 min. After that, 0.1 volume DNase inactivation reagent was 
added and mixed well with the mixture followed by 2 minutes incubation at RT while mixing 
2-3 times during this period. The mixture was then centrifuged at 10,000 x g for 1.5 min 
which resulted in a supernatant layer that contained the RNA. Then, the iScript cDNA 
synthesis kit (Bio-Rad, cat # 1708891) was used to synthesize cDNA by mixing 10 µL of 
RNA collected from the previous step with 4 μL 5X iScript reaction mix, 1 μL iScript reverse 
transcriptase and 5 μL nuclease-free water. The reaction mixture was placed in a thermal 
cycler to synthesize cDNA using the following program: 25°C for 5 min, 42°C for 30 min, 
85°C for 5 min and then 4°C indefinitely.  
The master mix for the real-time quantitative reverse transcription PCR (qRT-PCR) 
reaction was prepared by mixing 400 nM of forward primer, 400 nM of reverse primer, 7.5 
μL PerfeCTa SYBR Green FastMix for iQ (2X), 5.3 μL nuclease-free water with 1 μL 
cDNA. The sequences of primers (Purchased from Integrated DNA Technologies, Iowa, 
USA) required for qRT-PCR are listed in table 2.2. All the master mix components were 
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mixed together in an Eppendorf tube except for the cDNA which was pipetted directly to the 
wells of a 96-well PCR plate (Axygen, California, USA). The no template control (NTC) 
wells were left without any cDNA. After the rest of the master mix components were added 
to the wells, the 96-well PCR plate was sealed adequately with a cover film and then placed 
into the Multicolor PCR detection system (Bio-Rad, California, USA) and the qRT-PCR 
reaction was run using the following protocols. For IMP1: 95°C for 2 min, 95°C for 45 sec 
and 53°C for 30 sec. For 18S: 95°C for 2 min, 95°C for 45 sec and 60°C for 30 sec. The 
thermocycler was also programed to produce a melt curve for both IMP1 and 18S after the 
amplification cycles were completed. The melt cure was produced by increasing the 
temperature from 60°C to 95°C by 0.5°C increments with each increment lasting for 30 
seconds. A single peak following melt curve analysis indicated qPCR product specificity.  
To normalize IMP1 mRNA levels, the 18S rRNA was used as a reference gene. Actin 
is another commonly used reference gene but it is thought to be regulated by IMP1 levels and 
was not fit to use in this experiment since a reference gene should be unaffected by 
experimental conditions. The 18S rRNA fits this criterion since it has been previously used in 
similar experimental conditions (APE1 knockdown in HepG2 cells) in Dr. Lee’s lab and was 
shown to be unaffected by these experimental conditions. 
Table  2.2 qRT-PCR primer sequences 
Primers Sequences 
IMP1 Forward 5’-AAC CCT GAG AGG ACC ATC ACT-3’ 
IMP1 Reverse 5’-AGC TGG GAA AAG ACC TAC AGC-3’ 
18S Forward 5’-CGG CGA CGA CCC ATT CGA AC-3’ 
18S Reverse 5’-GCT GGA ATT ACC GCG GCT-3’ 
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2.5 Protein lysate extraction 
Cells stably transfected with APE1 variants (section 2.3) were harvested for protein 
lysate extraction when they reached 70-80% confluency in 6-well plates. Gene knockdown 
cells (sections 2.2 and 2.7) were harvested 24 hours after the last siRNA transfections. To 
extract protein lysate, the growth medium was removed and the cells were washed twice with 
2 mL PBS per well. Then, 150 μL of protein lysis buffer (50 mM Tris-Cl pH 8.0, 150 mM 
NaCl, 0.5% SDS and 1% Triton X-100) was added to each well. Lysate from every two wells 
of a 6-well plate were collected in one Eppendorf tube. Then, 4X volume acetone was added 
to the Eppendorf tubes which were vortexed and then stored at -20 °C to allow the proteins to 
precipitate overnight.  
After thawing, all the samples were centrifuged at 16,000 x g for 10 minutes at 4°C. 
Then, the acetone was removed using a pipette and the lysates were left to dry in the 
Eppendorf tubes at RT for 10 minutes. Next, 20 μL water was added to the lysate in each 
tube and left for 30 minutes to resuspend. The suspended lysates from each sample were then 
collected in new Eppendorf tubes. The total amount of protein in each sample was quantified 
using the Pierce BCA protein assay kit (Thermo Scientific, cat # 23225). This was done by 
first preparing a set of diluted albumin standards (2000 μg/mL, 1500 μg/mL, 1000 μg/mL, 
750 μg/mL, 500 μg/mL, 250 μg/mL, 125 μg/mL, 25 μg/mL). Then, the BCA working reagent 
was prepared by mixing 50 parts of BCA reagent A with 1 part of BCA reagent B. 200 μL 
working reagent was mixed with 10 μL of each protein sample in a 96-well plate and mixed 
properly on a plate shaker for 30 seconds. Next, the plate was incubated for 30 minutes at 
37°C, then left to cool to RT before measuring the absorbance at 562nm using Synergy 2 
(BioTek, Vermont, USA). A standard curve was then prepared by plotting the average 
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measurement for each albumin standard against its concentration. The standard curve was 
then used to determine the concentration of protein in each sample.       
2.6 Western blot analysis 
 Sixteen μL of protein (10-30 μg) was mixed with 4 μL of 5X SDS loading buffer 
(containing 5% β-mercaptoethanol) and then boiled for 10 minutes. Next, the samples and a 
prestained protein ladder were loaded onto a 10% sodium dodecyl sulfate (SDS) 
polyacrylamide gel and electrophoresed for 45-60 mins at 140 volts. After electrophoresis, 
the proteins on the gel were transferred to a 0.45 μm pore size nitrocellulose blotting 
membrane (Amersham™ Protran® Premium, GE Healthcare). Transferring was performed at 
100 volts for 1 hour at 4°C. After protein transfer was complete, the membrane was blocked 
overnight at 4°C with 20 mL of 1x TBST (0.05 M Tris-Cl pH 7.4, 0.03 M NaCl, 0.1% tween 
20) with 5% skim milk (SM).  
After blocking, the membrane was rinsed with 1xTBST. Then, primary antibodies 
diluted in 1xTBST with 1%SM or 5%BSA (depending on the antibody manufacturer 
protocol) were added to the membrane in order to detect target proteins. The manufacturers 
and dilutions of the primary antibodies are listed in table 2.3.  The membranes were 
incubated with the primary antibodies on a laboratory platform rocker for 1 hour at RT or 
overnight at 4°C (depending on the antibody manufacturer protocol). The membranes were 
then washed with 1xTBST to remove unbound antibodies. After that, secondary antibodies 
diluted in 1xTBST with 1%SM were added to the membrane to bind to the primary 
antibodies. The manufacturers and dilutions of the secondary antibodies are listed in table 
2.4. The membranes were then incubated with the secondary antibodies on a laboratory 
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platform rocker for 1 hour at RT and then washed with 1X TBST to remove unbound 
antibodies.  
 The membranes were developed using SuperSignal West Femto Maximum 
Sensitivity Substrate kit or SuperSignal West Pico Chemiluminescent Substrate kit according 
to the manufacturer’s protocol (Thermo Scientific, Illinois, USA). The developed membranes 
were then visualized using the FluorChem Q system (ProteinSimple, California, USA). 
Protein bands were imaged using the AlphaView Q software (ProteinSimple, California, 
USA) and were quantified by densitometry using the software’s multiplex band analysis 
option. To ensure consistency, identical rectangles were drawn around bands from different 
samples. The software converts the color density inside each rectangle into quantifiable 
numbers. The level of the protein of interest was normalized by the level of Thioredoxin. In 
some cases, double bands appeared for APE1 and E-Cadherin. This could be for a variety of 
reasons. For APE1, this has been frequently observed by other members in Dr. Lee’s lab and 
is thought to be a consequence of repeated freezing and thawing which results in a degraded 
form of APE1 protein. As for E-Cadherin, the double bands could also be the result of 
repeated thawing and freezing. Alternatively, the manufacturers of another E-Cadherin 
antibody (ab133597, Abcam) have reported in their protocol document that E-Cadherin 
protein has several cleavage sites which can result in more than one observable band between 
~80-120 kDa .         
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Table  2.3 Primary antibodies used for Western blot  
Primary 
antibody 
 
Manufacturer 
 
Product number Dilution 
APE1 Santa Cruz Biotechnology sc-17774 1:3000 
IMP-1 Santa Cruz Biotechnology sc-166344(D-9) 1:1000 
Thioredoxin Abcam ab26320 1:1000 
E-Cadherin Cell signalling 24E10 1:1000 
 
Table  2.4 Secondary antibodies used for Western blot 
Secondary 
antibody 
 
Manufacturer 
 
Product 
number 
Dilution 
Primary AB used 
against 
Goat anti-mouse 
IgM-HRP 
Santa Cruz 
Biotechnology 
sc-2064 1:4000 IMP-1 
Anti-mouse IgG-
HRP 
Promega W402B 1:4000 APE1 
Anti-rabbit IgG-
HRP 
Promega W401B 1:2000 
Thioredoxin, E-
Cadherin 
 
2.7 Knocking down IMP1 in APE1-knocked down cells 
Some experiments aimed to knockdown IMP1 levels in APE1 knocked-down cells. 
To achieve this, the cells were transfected twice with siRNA against APE1 or SN as 
explained in section 2.2, however 24 hours after the second transfection with siRNA, the 
cells were transfected with siRNA against IMP1 or SN (as a control) (as explained in section 
2.2 for 6-well plates). Cells were then incubated at 37°C in a CO2 incubator. Protein lysate 
was extracted after 24 hours as explained in section 2.5. Then, Western blot analysis was 
performed as explained in section 2.6. 
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2.8 Cycloheximide chase assay 
Cells were transfected twice with siRNA against APE1 or SN as described in section 
2.2. After 24 hours from the last transfection, medium was discarded and 2.5 mL fresh 
EMEM+10%FBS mixed with 300 μg/ml cycloheximide (dissolved in DMSO) was added to 
each well of the 6-well plate. The final percentage of DMSO in each well was 0.3%. Then 
the plates were placed in a 37°C CO2 incubator and protein lysate was collected as explained 
in section 2.5 at 0 (no treatment control), 1, 2, 4 and 6 hours. The protein lysate was then 
processed and quantified as explained in section 2.5. Western blot analysis was then 
performed as explained in section 2.6 to determine IMP1 protein levels at each time-point. 
2.9 Construction of the luciferase construct 
The psiCHECK-2 vector (Promega) enables the monitoring of changes in expression 
of the renilla luciferase. The 3’UTR regions of IMP1 were cloned downstream of the renilla 
translational stop codon. Therefore, if the 3’UTR contain sequences that regulate translation 
efficiency, the renilla activity would reflect such change. An advantage of psiCHECK-2 is 
that it contains a firefly luciferase gene which is expressed constitutively and thus allows for 
normalization of transfection efficiency.  
The 3’UTR regions of IMP1 were cloned into psiCHECK-2 plasmids by Dr. Maggie 
Li and Mr. Sebastian Mackedenski. The final psiCHECK-2 constructs used in this 
experiment contained either F1+F2 region or F3+F4 region of IMP1 3’UTR. These regions 
are shown in figure 2.1. The primers that were used to clone the 3’UTR regions into 
psiCHECK-2 are listed in table 2.5. Throughout this thesis, the F1+F2 region is referred to as 
the proximal half, and the F3+F4 region is referred to as the distal half.   
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Figure  2.1 The IMP1 3’UTR regions that were cloned into the luciferase constructs. The 
luciferase constructs used in this experiment contained either F1+F2 (nts 2069-5401) or 
F3+F4 (nts 5402-8708).   
Table  2.5 Primers used to clone IMP1 3'UTR regions into psiCHECK-2 
Primer Direction Sequence 
Imp1-3’UTR-F1 Forward 5’-ACCACTCGAGCCAGCCCCTCCCTGTCCCTT-3’ 
Imp1-3’UTR-F1 Reverse 5’-ACCAGCGGCCGCCATATGTAGAGAGGCCTT-3’ 
Imp1-3’UTR-F2 Forward 5’-ACCACATATGGAAAAGCCCATG-3’ 
Imp1-3’UTR-F2 Reverse 5’-ACCAGCGGCCGCTCACTCTTCTCAAATCAT-3’ 
Imp1-3’UTR-F3 Forward 5’-ACCACTCGAGATGATTTGAGAAGAGTGA-3’ 
Imp1-3’UTR-F3 Reverse 
5’-ACCAGCGGCCGCCATATGCAGCCCAATCGAT 
ATGG-3’ 
Imp1-3’UTR-F4 Forward 5’-ACCACATATGGGAGGGCTGGCCATGAGG-3’ 
Imp1-3’UTR-F4 Reverse 5’-ACCAGCGGCCGCTGGCTGAAACAACCTTCA-3’ 
 
2.9.1 Transfection of the luciferase constructs into cells 
 Cells were reverse transfected twice with siRNA against APE1 or SN as described in 
section 2.2. After 24 hours from the last siRNA transfections, cells were transfected with the 
luciferase constructs. For transfecting the luciferase constructs into cells, DNA plasmid- 
Lipofectamine 2000 complexes were prepared as follows (per well of a 96-well plate). 0.4 μL 
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Lipofectamine 2000 was mixed with 24.6 μL Opti-MEM in a tube. In a separate tube, a 
volume containing 280ng plasmid was mixed with enough Opti-MEM to make the total 
volume equal to 25 μL. Both mixtures were incubated at RT for 5 minutes. Then, the tubes 
were mixed and incubated at RT for another 20 minutes. During this incubation period, the 
cells that would be transfected were prepared as follows. First the growth medium was 
discarded and each well of the 6-well plate were washed with 0.5 mL PBS and then 300 μL 
0.25% trypsin-EDTA was added to each well. The cells were then incubated for 10-13 
minutes at 37°C in a CO2 incubator. Then, 2.5 mL EMEM+10%FBS medium was added to 
each well. The cells were counted as described in section 2.2. Enough volume of 
EMEM+10%FBS was used to dilute the cells to a final density of 80 x 104 cells/mL. Then, 
100 μL of cells was added per well in a 96-well plate. After that, 50 μL of the DNA plasmid-
transfection mix was added to each well and mixed adequately with the cells. The cells were 
then incubated for 48 hours at 37°C in a CO2 incubator.  
2.9.2 Luciferase assay 
The cells were lysed 48 hours after being transfected with the luciferase constructs. 
The luciferase activity, which reflects the translation efficiency of the construct, was assessed 
using the Dual-Luciferase Reporter Assay System kit (Promega, cat # E1910) and Synergy 2 
Multi-Mode Reader (BioTeK). The luciferase assay was performed according to the 
instructions in the Dual-Luciferase Reporter Assay System technical manual (Promega, # 
TM040). The firefly reporter gene is expressed constitutively, and therefore used to 
normalize renilla luciferase expression to account for different transfection efficiencies in 
each well.  
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Each biological replicates were run in duplicates. The luminescence from both renilla 
luciferase expression and firefly luciferase expression was measured using Synergy 2 as 
Relative Light Units (RLUs). For each well, the renilla luminescence was divided by the 
firefly luminescence to calculate the relative renilla luciferase activity. Averaged relative 
renilla luciferase activity was calculated from two wells for each biological replicate.  To 
compare between experimental groups SN and Si, relative renilla luciferase activity was first 
normalized against the relative renilla luciferase activity obtained with empty psiCHECK-2 
vector to account for possible differences in luciferase expression due to differences in the 
folding of the protein. The final relative renilla luciferase presented was then expressed 
relative to SN. 
2.10 Statistical analysis 
Statistical analysis was conducted using Prism software (GraphPad, version 7.04). 
Statistical analysis of Western blot analysis, qRT-PCR and luciferase assay data was 
performed with student’s t tests (two-tailed) for comparison of two groups. Differences with 
P < 0.05 were considered statistically significant. Statistical analysis of Western blot analysis 
data for comparison of more than two groups was performed using One-way ANOVA. 
Multiple comparisons between different groups were performed using Fisher’s LSD test. 
Differences with P < 0.05 were considered statistically significant. For the data represented 
in figure 3.3 in the results section, there were initially four biological replicates for WT. After 
running Grubb’s outlier test, it was determined that one of the biological replicates was an 
outlier thus it was removed and this resulted in n=3 for WT.    
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Chapter 3 Results 
3.1 IMP1 mRNA and protein expression in APE1 knocked-down cells 
 To determine if APE1 regulates IMP1 at the mRNA level, APE1 was knocked down 
by transfecting cells with siRNA against APE1. The level of IMP1 mRNA was then 
measured using qRT-PCR as shown in figure 3.1.  The IMP1 mRNA level in APE1 knocked-
down cells was similar to the level of IMP1 in SN-transfected cells (P>0.1, figure 3.1). This 
indicates that APE1 does not change the steady-state level of IMP1 mRNA. The control 
group SN in figure 3.1 (first bar on the left) has no error bar. This is because the experimental 
group Si-APE1 was expressed relative to the control group in each biological replicate. As a 
result, the control group in each biological replicate is always 1 and thus does not have an 
error bar. This is also true for all other figures in this thesis. 
To determine if APE1 regulates IMP1 at the protein level, IMP1 protein expression 
was measured after APE1 was knocked down in the cells. The protein level of APE1 and 
IMP1 were detected using Western blot and then quantified by densitometry (figure 3.2). 
APE1 protein levels were reduced to around 20% compared to SN-transfected cells. This 
decrease in APE1 protein levels was associated with an approximately 2-fold increase in 
IMP1 protein levels (figure 3.2.). The results in figures 3.1 and 3.2 showed that knocking 
down APE1 increased IMP1 protein levels but not IMP1 mRNA levels. This shows that 
APE1 regulates IMP1 at the protein level. In the following sections, experiments were 
designed to investigate the mechanism of APE1’s regulation of IMP1 expression. 
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Figure  3.1 IMP1 mRNA expression in APE1 knocked-down cells. Cells were transfected 
with si-APE1 (siRNA against APE1) or SN (scrambled-negative). IMP1 mRNA levels were 
measured using qRT-PCR. The results were normalized to 18S ribosomal RNA levels and 
then expressed relative to SN. The results shown were pooled from three different biological 
replicates (n=3). Error bar represents standard error of the mean (SEM). T-test was 
performed for statistical analysis. 
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Figure  3.2 IMP1 and APE1 protein expression in APE1 knocked-down cells. (A) Cells 
were transfected with either si-APE1 (siRNA against APE1) or SN (scrambled-negative). P1 
and P2 represent the first and second biological replicates, respectively. The cell lysates were 
collected and subjected to Western blot analysis. The two bands observed for APE1 is likely 
due to repeated freezing and thawing of samples which may have resulted in protein 
degradation. Both bands were used to quantify APE1. (B) The Western blot protein bands 
were quantified by densitometry. The IMP1 and APE1 protein levels in si-APE1 cells were 
normalized by Thioredoxin and then expressed relative to SN-transfected cells. The results 
were pooled using the two different biological replicates (n=2). Error bars represent standard 
error of the mean (SEM). T-test was performed for statistical analysis. * denotes P<0.05. 
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3.2 Stable transfection of wild-type APE1 and L104R, E126D and D148E variants into 
cells and their impact on IMP1 protein levels 
   The purpose of this experiment was to determine if overexpressing wild-type APE1 
or APE1 variants would have an impact on IMP1 protein levels. Since APE1 has multiple 
functions, APE1 variants with diminished/altered function were used to try to investigate the 
activity of APE1 which is required for regulating IMP1. As mentioned in section 1.2.2, APE1 
variants D148E, E126D and L104R retain full or slightly reduced AP-DNA endonuclease 
activity but have lost or altered RNA cleaving ability. Since the binding affinity of the APE1 
variants to mRNA substrates is as strong as wild-type APE1, the introduced APE1 variants 
are expected to compete with endogenous APE1 in the cells for binding to mRNA substrates. 
If the RNA cleaving ability of APE1 is required to regulate IMP1 protein levels, then 
overexpressing APE1 variants (which as mentioned have lost or altered RNA-cleaving 
ability) is expected to interfere with endogenous wild-type APE1’s ability to regulate IMP1.  
Stably transfected cells expressing exogenous wild-type APE1 or one of the APE1 
variants: L104R, E126D and D148E were generated by Dr. Chow Lee and Dr. Maggie Li. As 
a negative control, cells stably transfected with an empty vector were also generated. The 
IMP1 protein levels were detected using Western blot and then quantified by densitometry 
(figure 3.3). Cells expressing either exogenous wild-type APE1 or any of the three APE1 
variants have significantly lower protein levels of IMP1 as compared to the empty vector 
transfectants (p<0.05) (figure 3.3). The results also show that wild-type and all three APE1 
variants transfectants had similar IMP1 protein levels. This suggests that the APE1 RNA-
cleaving ability may not be necessary for APE1’s regulation of IMP1 protein expression.   
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Figure  3.3 IMP1 protein expressions in cells stably transfected with E (empty vector), 
WT (wild-type APE1) and APE1 variants L104R, E126D and D148E. (A) Western blot 
of a representative biological replicate for each of E, WT, L104R, E126D and D148E. (B) 
Western blot protein bands were quantified by densitometry. The levels of IMP1 in each 
transfectant were normalized by Thioredoxin levels and then expressed relative to empty 
vector transfectant. The results were pooled using a different number of biological replicates 
(WT, n=3), (L104R, n=4), (E126D, n=3) and (D148E, n=2). Error bars represent standard 
error of the mean (SEM). One-way ANOVA was performed for statistical analysis and * 
denotes P<0.05 when compared to empty vector (E).    
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3.3 Investigating the importance of IMP1 3’UTR in APE1’s regulation of IMP1 protein 
translation using a Dual Luciferase Reporter Assay  
The 3’UTR of IMP1 mRNA is known to be targeted by many regulatory factors as 
mentioned in section 1.3.3. To investigate if APE1’s regulation of IMP1 is mediated by 
APE1 directly or indirectly targeting IMP1 3’UTR, cells were transfected with siRNA 
against APE1 (to knockdown APE1) or SN (negative control). Then, psiCHECK-2 constructs 
fused to the regions of the IMP1 3’UTR were transfected into both SN and si-APE1 (siRNA 
against APE1) transfectants.  
To first confirm that APE1 level was successfully knocked down in si-APE1 
transfectants, a portion of the cell lysate was collected at the time the luciferase assay was 
performed and subjected to Western blot to detect APE1 protein levels which were quantified 
by densitometry (figure 3.4). The results in figure 3.4 confirm that APE1 was knocked down 
in si-APE1 transfected cells at the time the luciferase assay was performed. Next, to confirm 
that an empty psiCHECK-2 is expressed at the same level regardless of APE1 levels, empty 
psiCHECK-2 was transfected into both SN and si-APE1 transfectants. The results confirmed 
that APE1 levels do not influence empty psiCHECK-2 expression (figure 3.5A). 
To determine if IMP1 3’UTR is regulated by APE1 expression, SN and si-APE1 
transfectants were transfected with psiCHECK-2 fused to F1+F2 region (proximal half) or 
F3+F4 region (distal half) of IMP1 3’UTR. The IMP1 3’UTR regions were cloned 
downstream of the renilla translational stop codon in psiCHECK-2. Therefore, if the IMP1 
3’UTR contain sequences that regulate translation efficiency, the relative renilla luciferase 
activity would reflect such change. After 48 hours, the transfected cells were lysed and their 
luciferase activity was measured using a Luminescence detector (figure 3.5B).   
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Figure  3.4 APE1 was successfully knocked down in Dual Luciferase experiment. (A) 
Western blot of a representative biological replicate of cells transfected with SN vs si-APE1. 
(B) Western blot protein bands were quantified by densitometry. The level of APE1 in SN 
and si-APE1 transfectants were normalized by Thioredoxin levels and then expressed relative 
to SN transfectants. The results shown were pooled from a total of three different biological 
replicates (n=3). Error bar represents standard error of the mean (SEM). T-test was 
performed for statistical analysis and * denotes P<0.05. 
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Figure  3.5 The effect of IMP1 3’UTR on the relative renilla luciferase activity in APE1 
knocked-down cells. (A) Cells were transfected with either si-APE1 (to knockdown APE1) 
or SN (negative control) and then transfected with an empty psiCHECK-2 vector. The 
relative renilla luciferase activity was measured for both transfectants and then expressed 
relative to SN transfectants. This was done to confirm that psiCHECK-2 alone expresses 
renilla luciferase at the same level in both SN and si-APE1 transfectants. (B) si-APE1 and 
SN transfectants were transfected with either the F1+F2 or F3+F4 regions fused to 
psiCHECK-2. The relative renilla luciferase activity was measured for each transfectant and 
then expressed relative to Control. Control represents SN transfectants that were transfected 
with F1+F2 or F3+F4. The results in both A and B were pooled from three different 
biological replicates (n=3). Error bars represent standard error of the mean (SEM). T-test was 
performed for statistical analysis and * denotes P< 0.05. 
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 The luminescence change indicates that the F3+F4 (distal half) region of the 3’UTR 
of IMP1 enhanced the relative renilla luciferase activity by approximately 20% in APE1 
knocked-down cells as compared to SN transfectants (Control) (figure 3.5B). On the other 
hand, the F1+F2 region (proximal half) did not increase the relative renilla luciferase activity 
in APE1-knocked down cells compared to SN transfectants (figure 3.5B). This indicates that 
increased IMP1 protein expression, as a result of APE1 depletion, is due to increased 
translation mediated at least partially by the distal end of the 3’UTR of IMP1.   
As mentioned previously, the 3’UTR of IMP1 mRNA is known to be a target site for 
regulatory proteins and miRNAs. Therefore, APE1’s expression may regulate IMP1 
translation by indirectly influencing the presence of other factors that bind to the 3’UTR of 
IMP1 (in this case, the distal half of the 3’UTR).     
3.4 Investigating the effect of APE1 knockdown on IMP1 protein levels in a 
cycloheximide chase assay 
 To confirm that increased IMP1 expression as a result of APE1 depletion is not due to 
defective protein degradation, cycloheximide chase experiments were performed. Cells were 
transfected with si-APE1 to knockdown APE1 or with SN as a negative control. Then, both 
transfectants were treated with cycloheximide for 0, 1, 2, 4 and 6 hours. The level of IMP1 
protein was measured at each time point. Cycloheximide halts protein synthesis by binding to 
the E-site in the large ribosomal subunit and preventing translation elongation (Schneider-
poetsch et al., 2010). Therefore, protein levels are expected to gradually decrease after cells 
are treated with cycloheximide due to inhibited synthesis.   
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When SN transfectants were treated with cycloheximide, IMP1 protein level was 
reduced with time and at 6h the level was reduced to 15% as compared to the 0h control and 
this was statistically significant (figure 3.6B). This was an expected outcome since 
cycloheximide inhibits protein synthesis and the remaining IMP1 proteins are expected to 
degrade with time.  
When APE1 knocked-down cells were treated with cycloheximide (figure 3.7), IMP1 
protein level showed a statistically significant reduction after 1 hour of treatment. However, 
after that the IMP1 protein level began to increase gradually. At 6 hours, the IMP1 protein 
level returned to a level similar to the 0h control. This experiment showed that after 1 hour of 
treatment with cycloheximide, IMP1 protein level in APE1 knocked-down cells decreased at 
least as much as the IMP1 level in SN-transfected cells. This indicates that the observed 
increase in IMP1 protein levels in APE1 knocked-down cells is not due to defective IMP1 
protein degradation mechanism.  
Since cycloheximide halts the synthesis of global proteins, the expected outcome is 
that proteins would gradually degrade with time after cells are treated with cycloheximide. 
Cells transfected with SN as a negative control and then treated with cycloheximide showed 
that IMP1 protein were indeed degraded with time until it reached a significantly low level at 
6 hour as compared to the 0 hour control  (P<0.05). On the other hand, APE1 knocked-down 
cells treated with cycloheximide showed that the IMP1 protein level significantly decreased  
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Figure  3.6 Cycloheximide chase experiment for SN transfectants. (A) Cells were 
transfected with SN (negative control) and then after 24 hours were treated with 
cycloheximide for 0, 1, 2, 4 and 6 hours. Cell lysate was collected at each time point and 
subjected to Western blot analysis. (B) Western blot protein bands were quantified by 
densitometry. The level of IMP1 protein was normalized to Thioredoxin and then expressed 
relative to 0h. The results shown were pooled from three different biological replicates (n=3). 
Error bars represent standard error of the mean (SEM). One-way ANOVA was performed for 
statistical analysis and * denotes P<0.05.  
0h 1h 2h 4h 6h
0.0
0.5
1.0
Time post cycloheximide treatment (h)
E
xp
re
ss
io
n
no
rm
al
iz
ed
to
co
nt
ro
l
2h 4h
 
6h
 
1h
 
0h
Cycloheximide
IMP1
Thioredoxin
B
*
A
 57 
 
 
Figure  3.7 Cycloheximide chase experiment for APE1 knocked-down cells. (A) Cells 
were transfected with si-APE1 and then after 24 hours were treated with cycloheximide for 0, 
1, 2, 4 and 6 hours. Cell lysate was collected at each time point and subjected to Western blot 
analysis. (B) Western blot protein bands were quantified by densitometry. The level of IMP1 
protein was normalized to Thioredoxin and then expressed relative to 0h. The results shown 
were pooled from three different biological replicates (n=3). Error bars represent standard 
error of the mean (SEM). One-way ANOVA was performed for statistical analysis and * 
denotes P<0.05.  
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at 1 hour of treatment (P<0.05) and then went back up gradually until at 6 hours the IMP1 
protein level was similar to the level at the 0 hour control. This may indicate that APE1 
knockdown interferes with cycloheximide’s ability to inhibit IMP1 protein synthesis. 
Alternatively, this could indicate that APE1 knockdown enhances IMP1 translation which 
results in the reversal of the IMP1 protein level in later time points after treatment with 
cycloheximide.  
3.5 Investigating the effect of APE1 and IMP1 knockdown on the anti-invasive protein 
E-Cadherin 
 The invasiveness of cells is usually associated with the breakdown of cell-to-cell 
adhesion. One important protein that is necessary for cell-to-cell adhesion is E-Cadherin. The 
loss of E-Cadherin is indicative of cell invasiveness (Bozzuto & Ruggieri, 2010). To 
determine the separate effect of APE1 and IMP1 on E-Cadherin protein levels in cells, APE1 
and IMP1 were separately knocked down in cells and E-cadherin levels were measured. The 
protein levels were detected by Western blot and then quantified by densitometry.  
Knocking down APE1 in cells causes an increase in E-Cadherin protein levels (figure 
3.8). The trend of an increase in E-Cadherin when APE1 is knocked down was observed in 
three different biological replicates. Also, knocking down IMP1 using two different siRNA 
against IMP1 (si-CRD-BP-1 and siCRD-BP-2) in cells causes an increase in the E-Cadherin 
protein levels (figure 3.9). 
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Figure  3.8 E-Cadherin protein expression in APE1 knocked-down cells.(A) A 
representative Western blot showing E-Cadherin, APE1 and Thioredoxin protein expression 
in APE1 knocked-down cells compared to SN transfected cells. (B) Western blot protein 
bands were quantified by densitometry. The protein levels of E-Cadherin and APE1 in SN 
and si-APE1 transfectants were normalized by Thioredoxin and then expressed relative to SN 
transfectants. The results shown were pooled from a total of three different biological 
replicates (n=3). Error bars represent standard error of the mean (SEM). T-test was 
performed for statistical analysis and * denotes P<0.05. 
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Figure  3.9 E-Cadherin protein expression in IMP1 knocked-down cells. (A) A 
representative Western blot showing E-Cadherin, IMP1 and Thioredoxin protein expression 
in IMP1 knocked-down cells (using two siRNAs against IMP1/CRD-BP: siCRD-BP-1 or 
siCRD-BP-2) compared to SN transfected-cells. Here, E-Cadherin and IMP1 were detected 
on separate blots because they are closer in size than are E-Cadherin and APE1. As a result, 
they do not always separate enough on the gel. (B) Western blot protein bands were 
quantified by densitometry. The protein levels of E-Cadherin and IMP1 in SN and siCRD-BP 
transfectants were normalized by Thioredoxin and then expressed relative to SN 
transfectants. The results shown were pooled from two different biological replicates (n=2). 
Error bars represent standard error of the mean (SEM). T-test was performed for statistical 
analysis and * denotes P<0.05. 
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Knocking down APE1 or IMP1 caused an increase in E-Cadherin protein level (figure 
3.8 and figure 3.9). This increase was consistently observed in at least two different 
biological replicates in each knockdown experiment (APE1 or IMP1). In each of these 
biological replicates, E-Cadherin increased when APE1 or IMP1 were knocked down but the 
amount of E-Cadherin increase variated in different biological replicates. This resulted in 
large standard errors but the results proved to be reproducible.  
 Knocking down APE1 causes an increase in both E-Cadherin and IMP1 protein levels 
and knocking down IMP1 causes E-Cadherin protein levels to increase. In other words, E-
Cadherin and IMP1 have a positive correlation in APE1 knocked-down cells and an inverse 
correlation in IMP1 knocked-down cells. This indicates that APE1 does not regulate E-
Cadherin via IMP1 but suggest that both APE1 and IMP1 regulate E-Cadherin via separate 
pathways.   
To further confirm that APE1 and IMP1 regulate E-Cadherin via separate pathways, 
both APE1 and IMP1 were knocked down in the same cells and the E-Cadherin protein level 
was then measured using Western blot analysis. The rationale was that if the knockdown of 
IMP1 and APE1 causes an increase in E-Cadherin protein levels via separate pathways, then 
the knockdown of IMP1 while APE1 levels are already down will cause a further increase in 
E-Cadherin level. The results are shown in figure 3.10 (using siCRD-BP-1) and figure 3.11 
(using siCRD-BP-2). Knocking down APE1 increased both IMP1 and E-Cadherin protein 
levels as expected (figure 3.10). When APE1 knocked-down cells were transfected with 
siCRD-BP-1, the IMP1 protein level remained high. Transfecting siCRD-BP-1 against IMP1 
in APE1 knocked-down cells appears to increase the E-Cadherin protein level compared to  
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Figure  3.10 E-Cadherin protein expression in APE1 & IMP1 knocked-down cells (using 
siCRD-BP-1). (A) Western blot analysis showing E-Cadherin, IMP1, APE1 and Thioredoxin 
protein expression in APE1 & IMP1 knocked-down cells (using siAPE1 and siCRD-BP-1) 
compared to SN transfected cells. (B, C) Western blot protein bands were quantified by 
densitometry. The protein levels of E-Cadherin, IMP1 and APE1 in the transfectants were 
normalized by Thioredoxin and then expressed relative to SN transfectants. (n=1).  
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the E-Cadherin level in APE1 knocked-down cells that were transfected with SN instead of 
siCRD-BP-1.  
The results in figure 3.11 also confirmed that knocking down APE1 increases both 
IMP1 and E-cadherin protein levels. Again, the IMP1 protein level remained high when 
siCRD-BP-2 was transfected into APE1 knocked-down cells. Transfecting siCRD-BP-2 
against IMP1 in APE1 knocked-down cells appears to increase the E-Cadherin protein level 
compared to the level of E-Cadherin in APE1 knocked-down cells that were transfected with 
SN instead of siCRD-BP-2. 
The results confirmed the previous findings that APE1 knockdown increases both E-
Cadherin and IMP1 protein levels (figure 3.10 and figure 3.11). However, knocking down 
IMP1 protein levels in APE1 knocked-down cells was not achieved; when using siRNA 
against IMP1 mRNA, the IMP1 protein level remained high. IMP1 protein level remaining 
high in APE1 knocked-down cells even after IMP1 mRNA knockdown supports the notion 
that APE1 knockdown enhances IMP1 translation.  
 The inability to bring down IMP1 protein levels in APE1 knocked-down cells 
prevented the assessment of knocking down both proteins simultaneously on E-Cadherin 
levels. Although E-Cadherin levels appear to increase when APE1knocked-down cells were 
transfected with siRNA against IMP1, this should be considered as preliminary data since 
only one biological replicate was included. 
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Figure  3.11 E-Cadherin protein expression in APE1 & IMP1 knocked-down cells (using 
siCRD-BP-2). (A) Western blot analysis showing E-Cadherin, IMP1, APE1 and Thioredoxin 
protein expression in APE1 & IMP1 knocked-down cells (using siAPE1 and siCRD-BP-2) 
compared to SN-transfected cells. (B, C) Western blot protein bands were quantified by 
densitometry. The protein levels of E-Cadherin, IMP1 and APE1 in the transfectants were 
normalized by Thioredoxin levels and then expressed relative to SN transfectants. (n=1). 
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The knockdown of IMP1 or APE1 caused an increase in E-Cadherin protein levels. 
The upregulation of E-Cadherin is characteristic of Mesenchymal-to-Epithelial transition 
(MET) (Qian et al., 2014). In MET, the invasive and migratory properties of cancer cells are 
attenuated or reversed (Takaishi et al., 2016). The MET process is the reverse process of 
Epithelial-to-Mesenchymal transition (EMT) which is characterized by loss of cell-to-cell 
adhesion and increased invasive activity (Takaishi et al., 2016).   
 66 
 
Chapter 4 Discussion 
 
 The initial interest in studying the interaction between IMP1 and APE1 stemmed 
from the fact that IMP1 binds and stabilizes mRNAs such c-myc which were identified by 
our lab as mRNA targets that are cleaved by APE1 (Sparanese & Lee, 2007; Barnes et al., 
2009). This suggested that IMP1 may be directly shielding mRNAs from APE1. In an initial 
experiment in this thesis where APE1 was overexpressed in cells, proteins expressed from 
known mRNA targets of APE1 (such as c-myc and CD44) either did not express observable 
protein levels in HepG2 cells (the cell line used throughout this thesis) which were detected 
using Western blot analysis or the protein levels did not show a consistent trend of change 
after APE1 was overexpressed in the cells. Unexpectedly, overexpressing APE1 caused a 
change in the IMP1 protein level. This finding shifted the focus to investigating the 
regulation of IMP1 by APE1 in depth. Literature review suggested that several factors and 
pathways may be involved in mediating the interaction between APE1 and IMP1. For 
instance, as mentioned previously c-myc is cleaved by APE1 but is also a transcription factor 
known to promote IMP1 transcription (Barnes et al., 2009; Noubissi et al., 2011). Also, 
APE1 has been found to regulate miRNA levels in cells as mentioned previously (Dai et al., 
2013) while the IMP1 mRNA 3’UTR is known to be regulated by miRNAs (Busch et al., 
2016). These are some of the possible links between APE1 and IMP1. However, to date no 
published data has shown an APE1-IMP1 interaction. 
The aim of this thesis was to investigate the possible interaction between APE1 and 
IMP1 and enhance what is currently known about IMP1 regulation in cancer cells. HepG2, a 
liver cancer cell line, expresses abundant levels of IMP1(Gutschner et al., 2014). Also, 
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previous experiments conducted by members of Dr. Lee’s lab showed that HepG2 expresses 
high levels of cytoplasmic APE1 (unpublished). In addition, APE1’s endoribonucleolytic 
activity was first discovered in rat liver (Lee et al., 2009) and thus APE1 RNA cleaving 
activity is expected to play an important role in the cytoplasm. For all these reasons, the 
HepG2 cell line was used throughout this thesis.  
4.1 IMP1 protein expression is controlled by APE1 expression 
 In order to determine if APE1 regulates the expression of IMP1 at the transcriptional 
or post-transcriptional level, APE1 was knocked down in cells and then IMP1 mRNA and 
protein levels were measured. When APE1 was knocked down in cells, the level of IMP1 
mRNA was not affected (figure 3.1). This result shows that APE1 does not influence the 
steady-state level of IMP1 mRNA. To determine if APE1 regulates IMP1 at the translational 
level, the protein levels of IMP1 in APE1 knocked-down cells were measured. IMP1 protein 
levels in APE1 knocked-down cells increased approximately 2-folds as compared to SN-
transfected cells (control) (figure 3.2). These results suggest that APE1 regulates IMP1 at the 
translational level.  
 APE1 has multiple functions which can regulate gene expression. One of these 
functions is cleaving mRNA which is then further degraded. To investigate if APE1’s RNA 
cleaving ability is responsible for regulating IMP1 expression, APE1 variants with 
lost/altered RNA cleaving activity were overexpressed in cells. The three variants that were 
used are D148E, E126D and L104R. The D148E variant was associated with many cancers 
and along with variants E126D and L104R were associated with the neurological ALS 
disease (Olkowski, 1998; Smith et al., 2008; Gu et al., 2009). Previous functional 
characterization studies in our lab showed that APE1 variants D148E, E126D and L104R 
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retain full or slightly reduced AP-DNA endonuclease activity (Kim et al., 2014). The study 
also confirmed that the APE1 variants had binding affinities to mRNA substrates equal to the 
wild-type APE1. However, these variants had lost or altered RNA cleaving ability. The 
D148E variant lost its activity to cleave a short version of c-myc RNA in vitro while E126D 
and L104R cleave the same RNA substrate at unique sites different than those cleaved by 
wildtype APE1(Kim et al., 2014).   
Cells stably overexpressing exogenous wildtype APE1 or one of the APE1 variants 
L104R, E126D and D148E were generated in our lab. As a negative control, cells stably 
transfected with an empty vector were also generated. The level of IMP1 protein in these 
stable transfectants was then measured. The introduced APE1 variants are expected to 
compete with endogenous APE1 in the cells in binding to mRNA substrates. The rationale 
was that if the RNA cleaving ability of APE1 is required to regulate IMP1 protein levels, 
then overexpressing APE1 variants (with lost or altered RNA-cleaving ability) is expected to 
interfere with endogenous wild-type APE1’s ability to regulate IMP1 in cells. As a result, 
cells expressing exogenous wild-type APE1 are expected to have a stronger effect on IMP1 
protein levels as compared to cells expressing exogenous APE1 variants.   
 Overexpressing exogenous wild-type APE1 (WT) causes the IMP1 protein level to 
be reduced to around 30% compared to cells that were transfected with an empty vector (E) 
as a negative control (figure 3.3). This is consistent with the results in figure 3.2 which 
showed that IMP1 levels increased around 2-folds when APE1 was knocked down. The 
results in figure 3.3 also showed that all three APE1 variants caused IMP1 protein levels to 
significantly decrease compared to empty vector transfectants. However, the IMP1 protein 
level in all three variants transfectants was similar to the level in the wild-type APE1 
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transfectant. Also, the three variants transfectants had similar IMP1 protein levels compared 
to each other (figure 3.3).   
These results showed that overexpressing wild-type APE1 or any one of the three 
APE1 variants had a similar effect on the IMP1 protein level which is reducing IMP1 protein 
levels to ~ 30% or less of that of empty vector transfectants. Since D148E lost RNA cleaving 
ability and this loss did not affect its ability to regulate IMP1 protein levels, the results 
suggest that APE1 RNA cleaving ability is not responsible for regulating IMP1. Also, the 
APE1 variants L104R and E126D were also able to regulate IMP1 similar to the wild-type 
APE1 and since both variants have altered RNA cleaving ability, this supports the notion that 
APE1 endoribonuclease activity is not necessary for APE1 regulation of IMP1 protein levels.  
 It was first established that APE1 regulates IMP1 post-transcriptionally via knocking 
down APE1 and then measuring IMP1 mRNA and protein levels. Next, it was found that 
APE1 with lost or altered RNA cleaving ability had not effect on its ability to regulate IMP1 
protein levels. As mentioned, these results suggest that APE1’s effect on IMP1 expression 
may not be due to its RNA cleaving ability. The RNA cleaving ability could have directly 
affected IMP1 by cleaving the mRNA of IMP1. This possibility was ruled out based on the 
results from the APE1 knockdown experiment which were also supported by the results in 
the overexpression of APE1 variants experiment. To further confirm that APE1 does not 
cleave IMP1 mRNA, Dr. Maggie Li performed an mRNA degradation assay to test the effect 
of APE1 knockdown on IMP1 mRNA decay. In this assay Dr. Li treated APE1 knocked-
down cells with actinomycin D, which is a drug used to inhibit transcription, and then 
measured IMP1 mRNA levels at different time points. The results showed that IMP1 mRNA 
were degraded at the same rate in APE1 knocked-down cells compared to SN-transfected 
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cells (unpublished data). This finding also confirmed that APE1’s post-transcriptional 
regulation of IMP1 is not the result of APE1 (or any other intermediate factor regulated by 
APE1) cleaving/degrading IMP1 mRNAs. However, the possibility remained that APE1 may 
be regulating IMP1 mRNA translation efficiency without degrading IMP1 mRNA. This is 
discussed in the next two sections. APE1’s RNA cleaving ability could also affect IMP1 
indirectly such as by cleaving RNAs or factors that regulate IMP1. Nonetheless, the finding 
in this section suggested that APE1’s RNA cleaving activity is not directly responsible for 
regulating IMP1. However, this is not a definitive proof that APE1’s RNA cleaving ability is 
not required for regulating IMP1 since the experiments that showed that these APE1 variants 
had lost/altered RNA cleaving ability were conducted in vitro and on specific RNA 
substrates (Kim et al., 2014). Therefore, these APE1 variants may still possess RNA cleaving 
ability in vivo or it may be effective against other RNA substrates.  
4.2 Mechanism of APE1 regulation of IMP1 translation 
 The 3’UTR of any mRNA is a critical site for translational regulation by miRNAs and 
regulatory proteins (Lai, 2002). As discussed in section 1.3.3, the 3’UTR of IMP1 mRNA 
has been shown to bind to several miRNAs including the Let-7 family which are known 
translational repressors (Busch et al., 2016). The 3’UTR can also serve as a binding site for 
regulatory proteins that enhance protein expression (Szostak & Gebauer, 2013). In order to 
investigate whether APE1 regulates IMP1 translation through IMP1’s 3’UTR, a luciferase 
reporter assay was used. The two halves of IMP1 3’UTR: F1+F2 (proximal half) and F3+F4 
(distal half) were separately cloned into the psiCHECK-2 vector downstream of the renilla 
translational stop codon. 
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 It was first established that an empty psiCHECK-2 vector without the addition of the 
IMP1 3’UTR regions has equal translation efficiency in APE1 knocked-down cells as 
compared to SN-transfected cells. This is shown in figure 3.5A where the relative renilla 
luciferase activity in APE1 knocked-down cells and SN-transfected cells were essentially the 
same. 
 Then, the proximal region of IMP1 3’UTR (F1+F2) was assessed for its role in 
APE1’s regulation of IMP1. To perform this, psiCHECK-2 + F1+F2 was transfected into 
APE1 knocked-down cells and also into SN-transfected cells. The results in figure 3.5B 
showed that the addition of IMP1 3’UTR F1+F2 to psiCHECK-2 did not have an impact on 
the translation efficiency (represented by the relative renilla luciferase activity) of 
psiCHECK-2 in APE1 knocked-down cells as compared to SN-transfected cells.  
Finally, the distal region of IMP1 3’UTR (F3+F4) was assessed for its role in APE1’s 
regulation of IMP1. To do this, psiCHECK-2 + F3+F4 was transfected into APE1 knocked-
down cells and also into SN-transfected cells. The results in figure 3.5B showed that the 
addition of IMP1 3’UTR F3+F4 region to psiCHECK-2 caused an approximately 20% 
increase in the relative renilla luciferase activity in APE1 knocked-down cells as compared to 
SN-transfected cells which was statistically significant. This indicates that the F3+F4 region 
of IMP1 3’UTR has sites that are targeted directly or indirectly by APE1 and that APE1 can 
regulate IMP1’s translation efficiency through these 3’UTR sites.   
To recap, the previous sections showed that a decrease in APE1 protein levels causes 
an increase in IMP1 protein levels. It was shown in our lab that this regulation is not due to 
reduced degradation of IMP1 mRNA. Thus it was postulated that APE1 may play a direct or 
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indirect role in regulating IMP1 translation. It was then suggested that APE1’s RNA cleaving 
activity may not be required for its regulation on IMP1 expression. This section showed that 
APE1 negatively regulates the translation efficiency of IMP1 via the distal half (F3+F4) of 
IMP1 3’UTR. When APE1 was knocked down, the translation efficiency of the psiCHECK-2 
vector containing the F3+F4 region increased to around 20% and this was statistically 
significant. The question then arises whether this 20% increase in translation of a specific 
protein is biologically significant. The promoter used in psiCHECK-2 is not the same as the 
natural IMP1 gene promoter. Studies show that different promoters have different 
transcriptional efficiencies (Dale, 1989; Brown, 1993). Therefore, even if the same 
regulatory region (here it’s the distal half of IMP1 3’UTR) is fused to two different types of 
promoters, the level of translation and how much it changes depends on how strong or weak 
the promoter is (Dale, 1989; Brown, 1993). Furthermore, this ~20% may account for part of 
APE1’s regulation of IMP1. In other words, APE1 may regulate the IMP1 protein level in 
more than one fashion or via targeting more than one site. For example, the myogenic 
regulatory factor MYF5 binds to both the 3’UTR as well as the coding region of Ccnd1 
mRNA and promotes its translation. MYF5 was also found to enhance Ccnd1 transcription 
(Panda et al., 2016). Nonetheless, from the luciferase reporter assay results it can be 
concluded that the distal half of IMP1 3’UTR is at least partially responsible for IMP1’s 
regulation by APE1.  
As mentioned, the results showed that APE1 depletion requires the distal region of 
IMP1 3’UTR to cause an increase in IMP1 translation, though the mechanism is still 
undetermined. Studies have shown that the IMP1 3’UTR is targeted by several miRNAs and 
particularly by the let-7 family (Busch et al., 2016). In recent studies, it was shown that 
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APE1’s downregulation was associated with changes in the expression of miRNAs in HeLa 
and osteosarcoma cells (Dai et al., 2013; Antoniali et al., 2017). Among those miRNAs were 
Let-7b and Let-7i which were downregulated when APE1 was knocked down (Dai et al., 
2013). Based on the experimental results in this thesis and the literature review about IMP1 
and APE1, it is possible that the knockdown of APE1 causes the downregulation of particular 
miRNAs that normally target the distal region of IMP1 3’UTR and repress IMP1 translation. 
In other words, when APE1 is downregulated, these miRNAs are also downregulated and as 
a result, IMP1 translation is de-repressed. It remains to be determined how APE1 regulates 
the expression of these miRNAs. It is possible that APE1 acts as a redox coactivator of 
transcription factors that are required for transcription of these miRNAs. Alternatively, the 
RNA cleaving activity of APE1 may be involved in processing the precursor RNA transcripts 
to generate these miRNAs. Therefore, when APE1 is knocked down, less IMP1-repressing 
miRNAs are synthesized, and IMP1 expression is not repressed. This may partially explain 
the increase in IMP1 protein levels in APE1 knocked-down cells as compared to SN-
transfected cells. 
4.3 The impact of APE1 depletion on IMP1 protein in a cycloheximide chase assay 
 To determine if higher steady-state IMP1 protein level observed in APE1 knocked-
down cells compared to SN-transfected cells is due to slowed down IMP1 protein 
degradation, the cycloheximide chase experiment was performed. Cycloheximide is a drug 
that halts translation elongation and thus inhibits global protein synthesis in cells (Baliga et 
al., 1969). After protein synthesis inhibition, the proteins are expected to gradually degrade.  
SN-transfected cells were treated with cycloheximide for 0, 1, 2, 4 and 6 hours. The 
cell lysates were collected at each time point and then IMP1 protein levels were measured. 
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The results in figure 3.6B, which were pooled from three different biological replicates, 
showed that the IMP1 protein level gradually decreased with time until reaching a 
significantly low level (15%) at the 6-hour time point compared to the level at the 0-hour 
control (no-treatment control).  
Similarly, APE1 knocked-down cells were treated with cycloheximide for 0, 1, 2, 4 
and 6 hours. The cell lysates were collected at each time point and then IMP1 protein levels 
were measured. The results in figure 3.7B, which were pooled from three different biological 
replicates, showed that the IMP1 protein level significantly decreased at the 1-hour time 
point but then started to gradually increase until at the 6-hour time point it reached a level 
similar to the level at the 0-hour control (no-treatment control).  
This cycloheximide chase assay showed that after 1 hour of treatment with 
cycloheximide, IMP1 protein levels were slightly reduced in SN-transfected cells (figure 
3.6B) but were reduced even more in APE1 knocked-down cells (~50% of the level at the 0h 
control) and this reduction was statistically significant (figure 3.7B). In other words, the 
IMP1 protein level was downregulated in APE1 knocked-down cells at least as much as it 
was in SN-transfected cells. This indicates that the higher steady-level of IMP1 protein level 
observed in APE1 knocked-down cells is not due to defective IMP1 degradation.  
The unusual reversal of IMP1 levels in later time points after cycloheximide 
treatment in APE1-knocked down cells (figure 3.7B) was an interesting observation and may 
provide insight into APE1’s role in controlling IMP1 translation. Cycloheximide inhibits 
translation by binding in the E-site of the 60S ribosome to specifically a binding pocket 
formed by conserved nucleotides of 25S rRNA and a stretch of the ribosomal protein eL42 
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(Schneider-poetsch et al., 2010; Loubresse et al., 2014). This may suggest that APE1 
regulates ribosome biosynthesis and assembly and that APE1 knockdown causes a change in 
ribosome structure/function which prevents cycloheximide from binding to its binding 
pocket. In this case, the initial drop of the IMP1 protein level (at 1h) in APE1 knocked-down 
cells is possibly because there were still some APE1 proteins remaining in the cell (since 
siRNA against APE1 does not completely remove all APE1). When all the remaining APE1 
proteins were used up for cycloheximide translational repression, cycloheximide can no 
longer inhibit IMP1 mRNA translation. Thus, the IMP1 protein level gradually increases 
back to normal levels as shown in figure 3.7.  
In support of an APE1 role in regulating ribosome assembly/biosynthesis, 
unpublished findings in our lab showed that APE1 protein co-sediments with the ribosome 
subunits in a sucrose gradient. In the experiment, cytoplasmic extraction (the post 16,000 x g 
centrifugation supernatant) was loaded on a 7 to 47 % sucrose gradient to fractionate the 40S 
and 60S monosomes from the 80S ribosomes and polysomes. It was found that APE1 protein 
was associated with the 40S and 60S ribosome subunits. It was also found that when APE1 
was knocked down, the ribosomal protein RPS6 which is a component of the 40S subunit 
shifts to the 80S ribosome (unpublished data). Studies have shown that RPS6 is required for 
ribosomes biogenesis and can also bind to specific mRNAs including mRNAs with terminal 
oligopyrimidine (TOP) tract at their 5’UTRs (Roux et al., 2007; Hagner et al., 2011). In a 
separate study by Viscotto et al. (2009), APE1 was found to interact with several protein 
partners which were either ribosomal proteins such as the 40S ribosomal protein SA (RPSA) 
and the 60S ribosomal protein P0 (RPLP0), or were involved in ribosome biogenesis and 
rRNA processing such as Nucleophosmin 1 (NPM1) (Vascotto et al., 2009). All these 
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findings support the hypothesis that APE1 may be involved in regulating ribosome assembly 
and biogenesis and thus APE1 knockdown may cause a functional/structural change in the 
ribosome preventing cycloheximide from binding to its binding site on ribosomes. This may 
explain the resurgence of IMP1 levels in later time points after cycloheximide treatment in 
APE1-knocked down cells (figure 3.7B).  
The association of APE1 with ribosomal subunits (and not with translation competent 
80S ribosomes) along with the observation that APE1 knockdown resulted in ribosomal 
protein RPS6 to shift from the 40S subunit to the translation competent 80S ribosome 
(unpublished data) can alternatively suggest that APE1 is a negative regulator of ribosome 
assembly and translation. This may suggest that APE1 knockdown triggers the assembly of 
80S ribosomes and their binding to specific mRNAs. This is supported by polysome profiling 
by Dr. Maggie Li which showed that APE1 knockdown caused IMP1 mRNA to shift to 
heavy polysomes (i.e. more 80S ribosomes were recruited to IMP1 mRNA) (unpublished 
data). Since, cycloheximide can only bind and inhibit actively translating 80S ribosomes and 
not ribosomal subunits (Ramakrishnan et al., 2002; Schneider-poetsch et al., 2010), these 
aforementioned findings along with the observation that IMP1 protein levels are de-repressed 
in later time points after cycloheximide treatment in APE1-knocked down cells may suggest 
that APE1 knockdown triggers the assembly of new 80S ribosomes and their recruitment to 
IMP1 mRNA. As a result, more cycloheximide is needed to completely inhibit translation. 
When residual active ribosomes are unoccupied by cycloheximide after cycloheximide is 
depleted in the cell, IMP1 translation and protein synthesis is resumed.  
How APE1 knockdown or its possible downstream cellular consequences enhances 
the translation of specific mRNAs remains speculative. However, one possible route is the 
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mechanistic target of rapamycin (mTOR) pathway which is an upstream master regulator of 
translation. The mTOR pathway can be activated by different stimuli including, oxidative 
stress, growth factors, mitogens and hormones, and can regulate mRNA translation at its 
various stages. One way the mTOR pathway can enhance translation is by promoting the 
assembly of the initiation factor complex eIF4F at the 5’-end of the mRNA which is then 
followed by the binding of the ribosome to the mRNA and the initiation of translation 
(Yalcin et al., 2008; Jackson et al., 2015). There are two functionally distinct complexes 
known as mTORC1 and mTORC2. However, translation regulation is mostly controlled by 
mTOR1 which phosphorylates components involved in the regulation of translation including 
eIF4E-binding proteins (4E-BPs) which repress translation initiation by binding to eIF4F 
complex and inhibits its assembly on the 5’UTR of the mRNA. When the mTOR pathway is 
activated, mTORC1 hyperphosphorylates 4E-BPs which then dissociate from the eIF4F 
complex. This allows eIF4F to assemble on the 5’UTR of the mRNA and eventually initiate 
translation (Nandagopal & Roux, 2015).   
Although mTOR regulates global mRNA translation via the aforementioned 
mechanism, the mTOR pathway can also preferentially induce the translation of specific 
mRNAs such as mRNAs with long and structured 5’UTRs which include mRNAs encoding 
proteins involved in cell proliferation such as c-myc (Koromilas & Sonenberg, 1992; Zimmer 
et al., 2000). Also, mTOR selectively enhances the expression of mRNAs containing 
terminal oligopyrimidine (TOP) tract at their 5’UTRs which include proteins involved in the 
translation process such as elongation factors eEF1A and eEF2 and also ribosomal protein S6 
(RPS6) (Carroll et al., 2004; Nandagopal & Roux, 2015). These are some identified mRNAs 
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which translation is selectively enhanced by the mTOR pathway and it is very possible this 
pathway stimulates the translation of other specific mRNAs via yet unidentified mechanisms.   
Interestingly, mTOR activation has been associated with increased ribosome 
recruitment to mRNAs which leads to the formation of heavy polysomes. This was shown 
when insulin, a hormone known to activate the mTOR pathway, was used to treat cells which 
resulted in the increase of the formation of heavy polysomes (Gandin et al., 2014). When 
these cells were treated with Torin1, an mTOR inhibitor, these effects were reversed and 
heavy polysomes were reduced (Gandin et al., 2014). It is currently unknown whether APE1 
regulates IMP1 mRNA translation via the mTOR pathway. Nonetheless, one possible link 
between APE1 and the mTOR pathway is PTEN, a phosphoinositide phosphatase. Studies 
have shown that APE1 expression activates PTEN which is known to be a negative regulator 
of the mTOR pathway (Fantini et al., 2009; Lasarge & Danzer, 2014). Therefore, APE1 
knockdown can possibly prevent PTEN activation which enhances the mTOR pathway. Then 
the mTOR pathway can promote the translation of global mRNAs as well as specific mRNAs 
(and perhaps IMP1 mRNA) by recruiting more ribosomes to these mRNAs.   
 The mTOR pathway also regulates translation at the elongation step. Studies have 
shown that mTORC1 phosphorylates and inactivates the eEF2 Kinase (eEF2K) (Kenney et 
al., 2014). An activated eEF2K normally phosphorylates and inhibits eEF2 which mediates 
the translocation of the ribosome on the mRNA from one codon to the next during the 
elongation step (Kenney et al., 2014). The knockdown of APE1 seemed to reverse IMP1 
protein synthesis inhibition caused by cycloheximide which stops translation by blocking 
eEF2-mediated ribosome translocation. This gives rise to the speculation that APE1 
knockdown may activate the mTOR pathway which induces translation at the elongation 
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stage via activating eEF2-mediated ribosome translocation. This may suggest that APE1 
knockdown opposes cycloheximide’s eEF2-mediated inhibitory effect on translation 
elongation. This may serve as another possible explanation for why in APE1 knocked-down 
cells treated with cycloheximide, the IMP1 protein level gradually increases back to normal 
levels as shown in figure 3.7.          
 The RNA cleaving function of APE1 might be another possible mechanism given 
that tRNAs are very possible target of APE1 due to their secondary structures with single-
stranded loops. This possibility gives rise to the speculation that increased IMP1 translation 
in APE1 knockdown cells may be due to APE1 cleaving or binding to specific tRNA types 
for codons that are frequently present in IMP1 mRNA. The lack of these tRNAs may then 
become rate limiting in the translation of IMP1 mRNA. When APE1 is knocked down, these 
tRNAs would become available to be used readily in IMP1 mRNA translation and thus IMP1 
protein synthesis is enhanced. An example of  a protein that can regulate translation by 
cleaving tRNAs is angiogenin (ANG), a member of the RNase A superfamily (Fu et al., 
2009). Angiogenin is a multifunctional protein that was first identified as an angiogenic 
factor in tumors. The secretion of angiogenin is enhanced in response to hypoxic stress. 
Secreted angiogenin then binds to the receptors on the surface of adjacent cells which helps 
internalize angiogenin into the cell to promote angiogenesis (formation of new blood vessel 
growth) (Yamasaki et al., 2009). Angiogenin also has other functions including promoting 
cell proliferation and regulating rRNA translation (Tsuji et al., 2005). A relatively newly 
identified function of angiogenin is its inhibition of translation by cleaving tRNA in response 
to cellular stress (Yamasaki et al., 2009). APE1 is an essential multifunctional protein itself 
and has already been characterized to cleave specific RNA sequences (Kim et al., 2010), thus 
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it is also possible that APE1 represses IMP1 mRNA translation via cleaving/binding specific 
tRNAs required during the elongation stage of translation. This may seem contradictory to 
the results of overexpressing APE1 variants with lost/altered RNA cleaving ability which 
was discussed in section 4.1 suggesting that APE1’s regulation of IMP1 is not via APE1’s 
RNA cleaving ability. However, these APE1 variants may have minor differences in vivo in 
the presence of endogenous wild type APE1. Since these variants have altered/lost RNA 
cleaving ability demonstrated in vitro on specific RNA substrates (Kim et al., 2014), the in 
vivo data obtained with overexpression of these variants are not definitive proof that the 
RNA-cleaving activity of APE1 is not responsible for regulating IMP1 translation. 
Based on the different experiments performed, it became evident that APE1’s 
expression controls IMP1 translation. The pattern of change in the IMP1 protein level in 
APE1 knocked-down cells during the cycloheximide chase assay provided new insight into 
the possible role of APE1 in controlling translation. Several explanations have been proposed 
to explain the results of the cycloheximide chase assay. In order to determine which of these 
proposed explanations is true, more experimental work is required. One of the proposed 
explanations was that APE1 knockdown interferes with cycloheximide’s inhibition of IMP1 
translation. As mentioned, cycloheximide is known to specifically inhibit the eEF-2 mediated 
translocation step of translation elongation by binding along with a deacylated tRNA to the 
E-site of the 60S ribosome (Schneider-poetsch et al., 2010). To determine if APE1 depletion 
specifically affects this process and binding site, other known translation inhibitors can be 
used. Another drug that inhibits translation at the elongation stage is Anisomycin. However, 
this drug inhibits translation elongation by binding to the A-site of the 60S ribosome and 
competing with aminoacyl-tRNA to the peptidyltransferase centre (Grollman, 1967; Blaha et 
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al., 2009). Other drugs also exist that inhibit translation at different stages. For example, 
Pateamine A inhibits translation initiation by binding and blocking the activity of the 
translation initiation factor eIF4A (Schneider-poetsch et al., 2010). Treating APE1 knocked-
down cells with a translation initiation inhibitor such as Pateamine A and then measuring 
IMP1 protein levels would determine if APE1 knockdown interferes specifically with 
translation elongation inhibition. If these results indicate that APE1 knockdown interferes 
with translation elongation inhibition specifically, then treating cells with a translation 
elongation inhibitor such as Anisomycin may help determine if APE1 knockdown interferes 
with IMP1 mRNA translation elongation inhibition by causing defective ribosome biogenesis 
and thus interfering with the specific site that cycloheximide binds to in the E-site of large 
ribosome subunit.      
It was also suggested that APE1 knockdown interferes with cycloheximide’s 
translation inhibition via activating the mTOR pathway which induce global and specific 
mRNA translation. This can be put to test by treating APE1 knocked-down cells with the 
mTOR inhibitor Torin-1 (Gandin et al., 2014) and then treating cells with cycloheximide to 
determine if the change in IMP1 protein level would still behave the same compared to IMP1 
protein level in APE1 knocked-down cells which are only treated with cycloheximide as 
shown in figure 3.7B. Finally, it was also suggested that APE1 regulation of IMP1 translation 
is mediated by APE1 cleaving tRNAs and particularly those that are frequently needed to 
translate IMP1 mRNA. One way to test if APE1 does in fact cleave tRNAs is by incubating 
total RNA with purified APE1 proteins and then performing northern blot analysis to 
determine if tRNAs were cleaved. The pre-established method used in the experiment 
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performed by Fu et al. (2009) which tested angiogenin for its ability to cleave tRNAs in vitro 
can also be applied to test APE1’s ability to cleave tRNAs (Fu et al., 2009).    
4.4 The effect of APE1 and IMP1 knockdown on the anti-invasive protein E-Cadherin 
 When cancer cells develop invasive and migratory properties, they can spread 
throughout the entire body and become life threatening. Therefore, proteins that regulate 
cellular invasiveness are of particular importance. The invasiveness of HepG2 cells upon 
APE1 knockdown was assessed previously in the lab by matrigel cell invasion assay. The 
results clearly showed that APE1 knocked-down cells became more invasive than SN-
transfected cells (unpublished data). In light of the findings in this thesis, it was intriguing to 
investigate if the invasiveness caused by APE1 knockdown has to do with APE1’s regulation 
of IMP1. The initial idea was to knockdown APE1 and IMP1 (which increases when APE1 is 
knocked down) simultaneously in the same cells. The hypothesis was that if APE1 
knockdown causes invasion because of its upregulation of IMP1 protein levels, then 
knocking down both APE1 and IMP1 would abolish the effect. However, knocking down 
IMP1 after it has been upregulated as a result of APE1 knockdown proved to be difficult. 
The inability to bring down IMP1 protein levels in APE1 knocked-down cells prevented the 
assessment of the effect of double knockdown of APE1 and IMP1 on the invasiveness of 
cells in the matrigel cell invasion assay.  
Another way of monitoring cellular invasiveness is by measuring adhesion proteins 
that are upregulated or downregulated during cellular invasion. Invasiveness usually requires 
the breaking up of cell-to-cell adhesion bonds. The onset of invasion is typically 
characterized by an epithelial to mesenchymal transition (EMT). In this process, epithelial 
cells lose their cell-to-cell adhesion and acquire migratory abilities. E-Cadherin is the most 
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important protein for forming adherens junctions to bind cells to each other (Takeichi, 1988; 
Gheldof & Berx, 2013). Therefore, the loss of E-Cadherin is indicative of cellular invasion 
and is an important event during the EMT process. To determine how APE1 regulates E-
Cadherin levels, APE1 was knocked down in cells, and E-Cadherin protein levels were 
measured. As shown in figure 3.8, the E-Cadherin protein level was upregulated in APE1 
knocked-down cells (this was also confirmed by the results in figures 3.10 and 3.11). This 
was unexpected since the matrigel invasion assay showed that APE1 knocked-down cells 
became invasive while the process of EMT invasion is associated with a decrease in E-
Cadherin levels. Taken together, this suggests that APE1 knockdown induces invasion but 
not via the EMT pathway. 
When IMP1 was knocked down, E-Cadherin protein levels increased (figure 3.9). 
This inverse correlation between IMP1 and E-Cadherin is consistent with their expression 
patterns in embryonic, adult and cancer cells. Studies have shown that IMP1 is expressed 
during embryogenesis and in cancer cells but it is not expressed in normal adult cells (Gu et 
al., 2008). The opposite is true for E-Cadherin. E-Cadherin is expressed at low levels during 
specific stages of embryogenesis when cells are required to lose attachment to surrounding 
cells and migrate to populate certain regions of the embryo which is required for proper 
development (Takeichi, 1988; Huber et al., 1996). E-Cadherin is also downregulated in 
invasive cancer cells but is expressed at high levels in normal adult cells (Takaishi et al., 
2016). These studies are consistent with our finding that IMP1 knockdown causes an increase 
in E-Cadherin protein levels. Increased E-Cadherin is characteristic of the reverse process of 
EMT known as mesenchymal-to-epithelial transition (MET) which results in cells becoming 
less invasive. In MET, cells regain cell-to-cell adhesion junctions partly because of the return 
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of E-Cadherin to normal levels. IMP1’s role in invasion has been previously documented. 
IMP1 promotes cancer and invasion by binding to several oncogenic mRNAs and one 
example is LEF1 mRNA. A study by Zirkel et al. (2013) has also shown that IMP1 enhances 
EMT properties in tumor cells by binding to the mRNA of LEF1 and enhancing its 
expression (Zirkel et al., 2013). LEF1 is a transcription factor which actives the transcription 
of fibronectin and SLUG which are both known to be overexpressed in EMT-induced 
invasion (Dufies et al., 2012). Consistently, Zirkel et al. also showed that IMP1 knockdown 
induces MET morphological changes in tumor-derived cells such as enhancing their cell-to-
cell adhesion and reducing their migratory abilities (Zirkel et al., 2013). Furthermore, IMP1 
also binds and stabilizes the mRNA of CD44 which is a cell-surface glycoprotein involved in 
cell-cell interaction. The overexpression of CD44 leads to invadopodia formation which are 
actin-like filaments that give the cells the ability to migrate and metastasize to the blood and 
then the entire body (Vikesaa et al., 2006).  
The results in figures 3.10 and 3.11 are preliminary data (one biological replicate 
each) that may indicate that transfecting cells with siRNA against IMP1 in APE1 knocked-
down cells causes an increase in the E-Cadherin protein level. Further experimental work is 
required to confirm this. IMP1 protein levels remained high even after cells were transfected 
with siRNA against IMP1 when APE1 is knocked-down. This further supports that APE1 
depletion enhances the translation of IMP1 despite IMP1 mRNA knockdown. As mentioned, 
cycloheximide inhibits mRNA translation by binding to ribosomes and immobilizing them 
on mRNAs (Arava et al., 2003; He & Green, 2013) while siRNA causes the degradation of 
the mRNA. However, both cases would cause there to be less translatable IMP1 mRNA 
available in the cell. Nonetheless, when APE1 is knocked down, the level of IMP1 remained 
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high although the level of translatable IMP1 mRNA present in the cell presumably decreased 
after treatment with siRNA against IMP1 or with cycloheximide. This further supports what 
was suggested in section 4.3 that APE1 knockdown selectively increase IMP1 expression by 
inducing the recruitment of more ribosomes on IMP1 mRNA. Thus, although there are less 
translatable IMP1 mRNA present in the cell, when APE1 is knocked-down, IMP1 protein 
synthesis is increased because translation efficiency is increased. 
In summary this section shows that APE1 knockdown causes the upregulation of the 
protein levels of E-Cadherin and IMP1. The knockdown of IMP1 also causes the 
upregulation of E-Cadherin. These separate effects of APE1 and IMP1 on the anti-invasive 
protein E-Cadherin suggest that APE1 and IMP1 induce invasion via different pathways. 
While the overexpression of IMP1 appears to induce invasion via the EMT process which is 
also supported by other studies, the loss of APE1 expression also induces invasion (based on 
previous matrigel invasion assay) but most likely not via the typical EMT process (since E-
Cadherin, which decreases in EMT, increased when APE1 was knocked-down). Furthermore, 
IMP1 levels in APE1 knockdown cells remain high even after knocking down IMP1 mRNA. 
This further supports the findings that APE1 knockdown enhances IMP1 translation.  
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Chapter 5 Conclusion 
 
It was shown that APE1 regulates IMP1 protein in HepG2 cells at the translational 
level without altering IMP1 mRNA levels. The obtained results suggest but do not confirm 
that APE1’s RNA cleaving ability is dispensable in this regulation. This thesis also provides 
evidence that the 3’UTR of IMP1 is at least partially responsible for controlling its 
expression regulated by APE1. While APE1 does not seem to affect IMP1 protein 
degradation, it was also revealed by cycloheximide experiments that APE1may also be 
involved in translation elongation. The findings from this study, together with the results 
obtained previously in Dr. Lee’s lab, suggest that APE1 is a negative regulator of IMP1 
translation possibly by regulating ribosome assembly and recruitment of IMP1 mRNA. 
Double knockdown of APE1 and IMP1 presented in this thesis also provided evidence that 
APE1’s role in regulating cell invasion does not appear to be a consequence of its regulation 
of IMP1. 
The results in this thesis also give rise to interesting speculations open for future 
investigation. For instance, to determine if (and which) miRNAs regulated by APE1 target 
the IMP1 3’UTR region, APE1 knocked-down cells can be transfected with synthetic 
oligoribonucleotides which are inhibitory to miRNAs suspected to be regulated by APE1 and 
bind to IMP1 3’UTR such as Let-7 miRNA. If these miRNAs are actually involved in the 
APE1-IMP1 interaction, then it is expected that the effect of APE1 knockdown on IMP1 
protein levels would be reduced or abolished when cells are transfected with these miRNA 
inhibitors. Further experiments are also required to determine which activity(s) of the 
multifunctional APE1 protein is responsible for regulating IMP1. This can be achieved by 
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overexpressing APE1 variants with other loss of functions or by using small molecule 
inhibitors of each APE1 function. Furthermore, it was suggested that APE1 knockdown 
might interfere with cycloheximide’s binding site/mode of action on ribosomes translating 
IMP1 mRNA. To test this, other translation inhibitors can be used which inhibit translation at 
other gene expression stages or by binding to other sites (as discussed in section 4.3). Finally, 
APE1 knockdown induced invasion but this does not appear to be via the typical EMT 
pathway since E-Cadherin levels increased after APE1 knockdown. This can be further 
confirmed by determining the effect of APE1 knockdown on other proteins involved in the 
EMT process such as snail, twist and MMPs (Lin et al., 2011).   
This thesis hoped to expand our current understanding of IMP1 regulation in cancer 
while also revealing a novel role for APE1 as a possible translation regulator. The altered 
expression of both proteins has been associated with diseases and particularly cancer (Craig 
et al., 2012; Shah et al., 2017). However, the roles of both APE1 and IMP1 in pathologies 
are not completely understood. The new findings on the roles and regulation of both proteins 
can be possibly used to reinterpret and further understand their involvement in diseases and 
cancer.   
The altered expression of APE1 has long been associated with a plethora of diseases 
including cancer. APE1 has multiple activities but the different diseases linked to APE1 were 
attributed mainly to deficiencies in APE1’s DNA repair activity as well as its role as redox 
coactivator of different transcription factors (Shah et al., 2017). Consistently with APE1’s 
important and diverse roles in the cell, generating complete APE1 knockout in murine 
models was embryonically lethal, and it has not been possible to generate any cell lines that 
are completely APE1 deficient (Xanthoudakis et al., 1996). This proves that APE1 has 
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irreplaceable roles in the cell. Unsurprisingly, emerging studies continue to reveal new roles 
and activities for APE1 in the cell. Our finding that APE1 can regulate the translation of 
IMP1, an oncogene overexpressed in various cancer types, might suggest that APE1’s 
involvement in cancer and possibly other diseases is mediated via its potentially new role as 
a translation regulator.   
Carcinogenesis is a stepwise process that involves genetic and epigenetic changes 
which include the loss of gene expression of tumor suppressors such as P53 (You & Jones, 
2012). While tumor suppressors are deactivated, the expression of oncogenes such as c-myc, 
K-Ras and CD44 is activated and this promotes tumorigenesis and invasion (Marhaba & 
Zöller, 2004; You & Jones, 2012; Ischenko et al., 2013). The majority of studies have 
focused on understanding tumor initiation and transcriptional regulation of tumor suppressors 
and oncogenes. However, less is known about the regulation of cancer-associated genes after 
transcription. RNA-binding proteins (RBPs) play a major role in regulating gene expression 
at the post-transcriptional level and their role in carcinogenesis has been gaining more 
attention by cancer researchers (Glisovic et al., 2008; Pereira et al., 2018). In liver cancer 
cells for instance, a study showed that 116 RBPs were overexpressed more than 2-folds 
(Gutschner et al., 2014). The most upregulated RBP in liver cancer cells was IMP1. IMP1 is 
absent in adults but is overexpressed in many cancer types, including liver, testicular, breast, 
brain, colon, skin and ovarian cancer (Ioannidis et al., 2003, 2004; Hammer et al., 2005; Mu 
et al., 2013; Gutschner et al., 2014). The exact mechanism of its upregulation is not 
completely understood yet. However, the strong upregulation of IMP1 in liver cancer and 
many other cancer types implies that IMP1 might be a particularly important driver of 
carcinogenesis. In support of this, the effect of IMP1 loss of expression in different human 
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liver cancer cell lines was examined by Gutschner et al. (2014). The study showed that the 
depletion of IMP1 inhibited proliferation and induced apoptosis in all the examined cell lines 
and the strongest effect was observed in HepG2 cells (which was used throughout this thesis) 
(Gutschner et al., 2014). Additionally, an in vivo study using a murine xenograft model by 
Gutschner et al. (2014) showed that tumor growth strongly depends on IMP1 overexpression 
but not tumor initiation (Gutschner et al., 2014). Another study has also shown that IMP1 
expression is necessary to sustain the invasion and migratory properties of tumor cells (Zirkel 
et al., 2013). An increasing number of studies suggest that IMP1’s strong oncogenic roles 
stems from its ability to bind to oncogenic mRNAs, including c-myc, K-Ras and CD44, and 
control their post-transcriptional fate which includes their stability, expression level and 
localization (Livingstone, 2003; Bell et al., 2013; King et al., 2014 ). Thus, it appears that 
IMP1 plays an important role in promoting and sustaining cancer by acting as master 
regulator of the expression of other oncogenes at the post-transcriptional level. While 
understanding the regulation of any oncogene is a valuable addition to cancer research, 
understanding the regulation of an oncogene that can control the expression of multiple other 
oncogenes such as the case for IMP1 may have an even greater value in cancer research. 
Subsequently, finding ways to inhibit the expression of IMP1 can potentially contribute 
significantly to the clinical interventions in cancer.  
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